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Summary of Thesis
Approximately 170 million individuals worldwide have been diagnosed with 
Diabetes Mellitus and between 85-90% of the total population have Type 2 
Diabetes Mellitus. Health care is facing an epidemic not only of Diabetes Mellitus 
but also of the consequence of the attendant morbidity including macro and 
micro diseases of the vascular system. Of particular interest for the purposes of 
this thesis, is the progression to nephropathy and development of cardiovascular 
risk of a proportion of this population and the investigation of strategies that may 
slow the decline to end stage renal failure and the need for renal replacement 
therapy or premature death due to cardiovascular disease.
Initially, screening practice for microalbuminuria was altered, with patients being 
identified during their clinic visit, rather than retrospectively. In addition, data on 
blood pressure levels and antihypertensive agents prescription was collected and 
collated.
Subsequently, a nurse specialist optimised the risk factor management of a 
cohort of patients with Diabetic Nephropathy using an algorithm driven evidenced 
based approach.
Finally, analysis was undertaken of the factors that might contribute to the 
development of anaemia in diabetic nephropathy and hence to increased 
cardiovascular risk.
The work described in this thesis demonstrates the inherent complexities of 
dealing with a problem that involves the maintenance of health within a system 
that has been set up primarily to deal with the consequences of illness.
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1.1 Aims
The overall aim of the work presented in this thesis is the examination of a 
cohort of patients with diabetes, in particular the screening and identification 
for diabetic nephropathy and the subsequent management of the renal and 
cardiovascular disease of those identified as being at risk. The impact of the 
introduction of a nurse specialist to establish evidence-based best practice for 
screening and hypertension treatment was evaluated and the impact of the 
change of practice measured against previous historical data.
Following this, a cohort of diabetic patients without nephropathy were 
evaluated to establish whether factors could be identified that might contribute 
to the development of anaemia in the early stages of the disease process and 
before the development of nephropathy.
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1.2 Diabetes Mellitus
1.2.1 Definition
The term Diabetes Mellitus describes a metabolic disorder of multiple 
aetiology characterised by chronic hyperglycaemia with disturbances of 
carbohydrate, fat and protein metabolism resulting from defects in insulin 
secretion, insulin action, or both [1]. The abnormalities of metabolism are due 
to deficient action of insulin on target tissues resulting either from insensitivity 
to or lack of insulin. In their review of 1999 the World Health Organisation 
recommended that the terms "insulin-dependent diabetes mellitus" and "non­
insulin-dependent diabetes mellitus" and their acronyms "IDDM" and "NIDDM" 
no longer be used. [2] These terms have led to confusion, as the classification 
was treatment based rather than pathogenesis based.
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1.2.2 Classification
The World Health Organisation report of 1999 classified Diabetes Mellitus into 
the following categories
Type 1 Diabetes Mellitus
Type 1 Diabetes Mellitus (formerly known as ‘insulin-dependent diabetes) is 
an autoimmune T cell mediated disease process caused by the destruction of 
the p cells of the pancreas and leading to absolute insulin deficiency. The 
incidence of Type 1 Diabetes Mellitus varies considerably worldwide, with 
Scandinavia having the highest incidence for example, Finland has an 
incidence of 35 cases per 100,000 per year) in contrast to Japan and China 
where the incidence is between 1 to 3 cases per 100,000 per year and 
Northern Europe and the United States where the rate is between 8 to 17 
cases per 100,000 per year [3],
Age at diagnosis most frequently is around 11 years of age in females and 14 
years in boys, with no gender differentiation in numbers diagnosed. In 
addition, it is believed that there are both genetic and environmental factors 
involved in the susceptibility for the development of Type 1 Diabetes Mellitus.
3
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus has replaced the term ‘Non Insulin Dependent 
Diabetes’ the latter term causing confusion, as many Type 2 diabetics require 
insulin to control their hyperglycaemia.
Type 2 Diabetes Mellitus affects about 2 per cent of the Caucasian population 
in the western world. The prevalence rises with age, reaching around 10% in 
the population over 70 years of age [4]. The prevalence of Type 2 Diabetes 
Mellitus is highest in some Pacific islands, intermediate in countries such as 
India and the United States, and relatively low in Russia and China [3]. This 
variability is thought to be due to genetic, behavioural, and environmental 
factors [4].
The young and middle-aged of Asian or Afro Caribbean extraction who live in 
western cultures have an increased prevalence of around 5% or more [5]. Age 
at diagnosis has most commonly been around 40 years rising to a peak at 
around 60 to 65 years, however, recent reports have highlighted the incidence 
of childhood obesity which has resulted in up to one third of Americans under 
20 years diagnosed with diabetes, having Type 2 disease.
It is thought that Type 2 diabetes is due to a combination of insulin resistance 
and a decrease in insulin secretion [1]. Susceptibility is thought to be 
determined by both genetics and environment. The lifetime risk for a first- 
degree relative of a patient with type 2 diabetes is five to ten times higher than 
that of age- and weight-matched subjects without a family history of diabetes 
[6] but even among groups with increased genetic risk for diabetes, 
environmental factors play a major role in the development of diabetes. For
4
example, the prevalence of diabetes among Pima Indians in Mexico (6.9 per 
cent) is less that one-fifth that of Pima Indians (38 per cent) living in the 
United States [7]
In addition to these two main types of diabetes, there are two other types of 
diabetes mellitus, namely specific and gestational, which will not be discussed 
in detail as part of this thesis.
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1.2.3 Prevalence of Diabetes Mellitus
The World Health Organisation estimated recently that there were 171 million 
individuals worldwide with diabetes. It is projected that by the year 2030 this 
number will have increased to 366 million [8]
Although diabetes is regarded by some as a disease of the developed world, 
the projected rise in prevalence is most marked amongst individuals in the 
developing world between the ages of 45-60 years. (Figure 1)
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Figure 1: Projected numbers of individuals with diabetes by 2030 in the 
developed and developing world
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Adapted from: Global Prevalence of Diabetes: Estimates for the year 2000 
and projections for 2030. Wild S, Roglic G, Green A, Sicree R, King H 
Diabetes Care 27:1047-1053, 2004 [8]
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1.2.4 Comorbid complications of Diabetes Mellitus
The proportion of individuals suffering from Type 2 Diabetes Mellitus is 
between 85-90% of the total diabetic population worldwide and health care is 
facing an epidemic not only of Diabetes Mellitus but also of the consequence 
of the attendant morbidity. There are many comorbid complications of Type 2 
Diabetes Mellitus including macro and micro diseases of the vascular system 
such as ischaemic heart disease, peripheral vascular disease, retinopathy 
and nephropathy.
In view of this and the levels of mortality if this patient group progress to 
requiring renal replacement therapy, the remainder of this thesis will focus on 
Type 2 Diabetes Mellitus and its consequences, in particular the management 
of cardiovascular disease and nephropathy given the direct relationship that 
exists between decreased Glomerular Filtration Rate (GFR) as a risk 
association with cardiovascular disease (CVD) and the fact that for patients 
with end stage renal disease (ESRD), the major cause of death is CVD.
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1.3Survival of patients with Type 2 Diabetes Mellitus on Renal 
Replacement Therapy
The importance of prevention of development of nephropathy in patients with 
Type 2 Diabetes Mellitus is emphasised by the prognosis of individuals who 
progress to the requirement for renal replacement therapy. In contrast to 
individuals with other renal diseases, patients with diabetic nephropathy have 
significantly worse survival (Figure 2) and although survival on dialysis in 
general has improved over time, as technology and techniques have 
improved, the differences between diabetic and non-diabetic patients have 
remained (Figure 3).
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Figure 2: Prognosis of diabetic patients on dialysis
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Adapted from: Marcelli et at; Prognosis of diabetic patients on dialysis: Data from the 
Lombardy Registry, Nephrology Dialysis and Transplantation 1995 Oct, 10: 1895-1900 [9 ]
Figure 3: European two year death rates among dialysis patients with 
Type 2 diabetic End Stage Renal Disease versus nondiabetic (adjusted 
for the age, gender and country distribution of incident patients in 1999)
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JD. Renal Replacement Therapy for diabetic end-stage renal disease: Data from 10 
registries in Europe (1991-2000). Kidney International 67,1489-1499, 2005 [1 0 ]
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1.4 Cardiovascular disease and Type 2 Diabetes Mellitus
Epidemiological studies have shown increased rates of Coronary Heart 
Disease (CHD), angina, myocardial infarction (both fatal and non-fatal) and 
sudden cardiac death amongst patients with diabetes [11] . The spectrum of 
diabetic disease has been described as a range from hyperinsulinaemia and 
impaired fasting glucose through to Type 2 diabetes mellitus. Increased risk of 
CVD does not start with Type 2 diabetes but rather extends across the entire 
spectrum of diabetic disease. A review by Tziakis et al [12] in 2005 of the 
cardiovascular risk across this diabetic syndrome documented a progressively 
increasing risk of cardiac events from hyperinsulinaemia to Type 2 diabetes 
as illustrated in Figure 4.
Type 2 Diabetes Mellitus has been shown to be associated with a two to four 
fold increased risk of coronary heart disease [13] and individuals with Type 2 
Diabetes Mellitus without CVD have the same risk of CHD as non diabetic 
individuals with a previous history of CVD.[13] In addition, women with 
diabetes lose their inherent protection against CVD.
Data from the Finnish Multinational monitoring of Trends and determinants of 
Cardiovascular Disease showed that the mortality rate for patients with Type 2 
diabetes who suffer a myocardial infarction was increased by 25%, a rate for 
out-of-hospital mortality rate which was increased by 25% and a one year 
mortality rate increased by 97%[14].
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The impact of cardiovascular disease in Type 2 diabetes is highlighted by the 
fact that 65 percent of all the deaths of patients with Type 2 diabetes are due 
to cardiovascular disease.
Strategies to delay or prevent the development of or improve the 
management of cardiovascular disease and its attendant additional 
comorbidity, including anaemia in this high risk group form the basis of the 
studies undertaken and reported here.
14
1.5 Nephropathy and Type 2 Diabetes Mellitus
Previously, the risk of developing comorbidity, such as nephropathy, was 
believed to be significantly lower for patients with Type 2 diabetes than for 
those with Type 1 disease. However, studies now confirm that the risk is 
similar and that the timelines for development of renal failure and the rate of 
decline in GFR are comparable [15] [16] (Figure 5).
The incidence of end stage renal failure caused by diabetic nephropathy is 
increasing worldwide although this overall figure masks the fact that some 
commentators have reported a decline in the incidence of Type 1 
nephropathy. Data reported from Sweden, in 1994, compared patients 
diagnosed in the 1960s with those from the 1990s and demonstrated a 
significant decline in the incidence of persistent albuminuria from 30 to 8.9%. 
[17]. The authors hypothesised that this decline might be due to improved 
glycaemic control in the more recent cohort, but it has not been possible to 
replicate this finding in other centres. What is certainly in no doubt is the 
increasing incidence and prevalence of nephropathy in patients with Type 2 
diabetes, with diabetes being the most common cause of end stage renal 
failure world wide [4].
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Figure 5: Cumulative prevalence of renal failure in Types 1 and 2 
Diabetes Mellitus
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Adapted from Hasslacher C, Ritz E, Wahl P, Michael C. Similar risks of nephropathy in 
patients with Type I or Type II diabetes mellitus. Nephrology Dialysis Transplantation. 
1989;4:859-63. [18]
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The changing impact of diabetes as the primary renal diagnosis in patients 
presenting for renal replacement is clear when reviewing registry data from 
the European Dialysis and Transplant Association (EDTA). The EDTA noted 
in 1974, that diabetic nephropathy is one of the ‘rarer causes’ of presentation 
and acceptance for renal replacement therapy and in 1975, it was included for 
the first time as a separate entity for reporting purposes and had an incidence 
of around three percent. Since then, the EDTA registry changes in both 
incidence and prevalence of diabetic nephropathy are marked and reported in 
Table 1, although the collated data masks significant differences between 
countries.
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Table 1: European Crude Incidence and Prevalence for Diabetic and Non 
Diabetic Renal Disease (pmp)
Incidence Type 2 Non-Diabetic
(95% Cl)________Diabetic Nephropathy__________ Renal Disease________
1991-1992 7.1 (6.6-75) 67.8 (66.4-69.2)
1999-2000 17.9(17.2-18.6) 93.8 (92.2-95.3)
Prevalence 
(95% Cl)
Type 2
Diabetic Nephropathy
Non-Diabetic 
Renal Disease
1991-1992 15.7(15.0-16.3) 455.8 (452.2-459.4)
1999-2000 44.5 (43.5-45.6) 607.2(603.2-611.2)
Adapted from: Van Dijk PCW, Jager KJ, Stengel B, Gronhagen-Riska, C, Feest TG, Briggs 
JD. Renal Replacement Therapy for diabetic end-stage renal disease: Data from 10 
registries in Europe (1991-2000). Kidney International 67,1489-1499, 2005 [1 0 ]
Changes in the underlying diagnosis of individuals presenting for renal 
replacement therapy (RRT) over the last twenty years are also highlighted in 
data from the United States Renal Data System where, in the 1980s, diabetic 
nephropathy comprised 28% of the RRT population and by 2006 this rate had 
risen to over 50% and was the most common presenting diagnosis! 19]. Data 
from the most recent UK Renal Registry report has highlighted the impact of 
diabetic nephropathy in patients starting renal replacement therapy and is 
described in Figure 6 [20].
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Figure 6: Primary Renal Diagnosis of patients starting Renal
Replacement Therapy: UK 2006
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Adapted from: Ansell D, Feest TG, Tomson C, Williams AJ, Warwick G, UK Renal Registry 
Report 2006, UK Renal Registry, Bristol, UK
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The increase in the numbers of individuals being diagnosed with Type 2 
Diabetes Mellitus at an early age has caused a commensurate increase in the 
numbers of individuals exposed to longer time scales of hyperglycaemia. 
Changes in the lifestyle of young adults predispose them to obesity and along 
with lack of regular exercise leads to a subsequent increase in susceptibility 
for developing Type 2 Diabetes Mellitus. Traditionally Type 2 Diabetes 
Mellitus was a disease of the elderly and as more individuals live longer the 
numbers at risk are increasing. Part of this increase is due to better glycaemic 
and blood pressure control which means that individuals with Type 2 Diabetes 
Mellitus are surviving long enough to develop the complications of diabetes 
[15].
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1.6 Development of cardiovascular disease and nephropathy
The development of cardiovascular disease and nephropathy in patients with 
Type 2 diabetes has been linked with a number of shared risk factors which 
are illustrated in (Figure 7). Of particular interest in terms of disease 
management are those factors which are capable of modification
Figure 7: Factors contributing to development of Cardiovascular 
Disease and Nephropathy in Type 2 Diabetes Mellitus:
Hypertension
Obesity
Proteinuria
Glycaemic Control
Diabetic
Nephropathy
and
Cardiovascular
disease
Smoking
Lipids
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1.6.1 Glycaemic control and the development of cardiovascular disease
and nephropathy
It remains a matter of discussion whether increased cardiovascular risk in 
patients with diabetes mellitus is associated with or caused by 
hyperglycaemia. Analysis of data from the UKPDS [21] established a linear 
relationship between increased HbAic levels and the risk of fatal or non-fatal 
myocardial infarction (Ml), fatal or non-fatal stroke, amputation or death from 
peripheral vascular disease and heart failure. After 10 years, the obtained 
HbAic in the intensive group was 7.0% versus 7.9% in the conventional group. 
[22]. This small difference in HbAic was associated with a 16% decreased 
risk for Ml but this trend in reduction in macrovascular events did not reach 
statistical significance at the 5% level and the risk of diabetes related death or 
all-cause mortality was not changed. It has been hypothesised that the 
inability to prove the benefit of improved glycaemic control on macrovascular 
endpoints in this study may have resulted from the small achieved difference 
in HbA1c.
It has been demonstrated in Type 1 Diabetes Mellitus that intensive control of 
blood glucose levels, reduce the proportion of patients developing diabetic 
nephropathy. The Diabetes Control and Complications Study [23] was 
designed to investigate whether Intensive Therapy (IT) when compared to 
Conventional Therapy (CT) would affect the risk of onset and progression of 
complications. The risks of the microvascular complications over the average 
of 6.5 years of follow-up were reduced by 26-63% with intensive versus 
conventional therapy. The IT group achieved a median HbA^ throughout the
22
study of 7.2% vs. 9.1% in the CT group (p<0.001). Early renal damage, the 
appearance of microalbuminuria (defined as Albumin Excretion Rate (AER) > 
40 mg/24 hours) was reduced by 60%. In addition, clinically significant renal 
damage (defined as Albumin Excretion Rate (AER) of > 300 mg/24 hours) was 
reduced by 54%.
Hyperglycaemia may produce end organ damage in the kidney both by direct 
effects on kidney tissue or by the stimulation of substances which have an 
effect on specific components of the kidney. These substances include 
hyperglycaemic induced activation of protein kinase C and subsequent 
increases in levels of Vascular Endothelial Growth Factor (VEGF) and 
Transforming Growth Factor -Beta (TGF-Beta) which in the case of VEGF 
leads to changes in vascular permeability and angiogenesis [24] [25] [26] and 
in the case of TGF-Beta stimulates collagen production leading to fibrosis 
[27] [28].
In addition to activation of the protein kinase C pathway, hyperglycaemia 
activates the renin-angiotensin system, thereby contributing to the 
development of cardiovascular disease and diabetic nephropathy. The 
production of substances capable of modifying the action of the renin- 
angiotensin system have provided the main therapeutic option in the slowing 
of progression of diabetic nephropathy.
23
1.6.2 Hypertension and the development of cardiovascular disease and
nephropathy
Hypertension is present in large numbers of patients with Type 2 diabetes at 
diagnosis. One study of over 3500 newly diagnosed patients found that thirty 
nine percent were already hypertensive [29]. Hypertension was strongly 
associated with obesity and an increased risk for cardiovascular morbidity and 
mortality.
An increase in left ventricular mass is a common occurrence in hypertension. 
This left ventricular hypertrophy (LVH) is associated with an increased risk of 
cardiovascular events such as angina, myocardial infarction, stroke, heart 
failure and sudden death [30], [31], [32]. In addition, it has been reported that 
there is a higher incidence of ventricular arrythmias in patients with LVH when 
compared with those without LVH [33]. The importance of LVH as a risk factor 
for cardiovascular events and the progression of kidney disease was 
confirmed in the RENAAL study where LVH was associated with the primary 
composite endpoint of doubling of serum creatinine, End Stage renal disease 
(ESRD) or death (hazard ratio=1.44, p=0.011) [34]. In the same study, LVH 
was also associated with the composite end point of doubling of serum 
creatinine and ESRD (hazard ratio=1.42, p=0.031) as well as cardiovascular 
events (hazard ratio=1.68, p=0.001). The impact of anaemia in the 
development of LVH has been well documented in ESRD and in addition it 
has been observated by Ritz and others that the onset of anaemia in patients 
with Type 2 diabetes is more precipitous and the degree of anaemia is more 
than would be expected with levels of GFR than in patients with other causes 
of ESRD.
24
The role of hypertension in the development of nephropathy is best 
understood by analysis of the impact of correction of hypertension on the 
progression of diabetic renal disease. Current data suggests that blockade of 
the Renin-Angiotensin-Aldosterone system (RAAS) and the subsequent 
decrease in blood pressure is effective in patients with Type 2 diabetes [35], 
[36], [37]. There remains controversy over the most appropriate blood 
pressure target although evidence from a large randomised double blind trial 
found that an achieved Systolic Blood Pressure(SBP) >149 mmHg was 
associated with a 2.2-fold increase in the risk for doubling serum creatinine 
compared with SBP<134 mmHg [38]. Progressive lowering of SBP to 120 
mmHg was associated with improved renal and patient survival, an effect 
independent of baseline renal function. Below this threshold, all-cause 
mortality increased. An additional renoprotective effect of irbesartan, 
independent of achieved SBP, was observed down to 120 mmHg. There was 
no correlation between diastolic BP and renal outcomes. These investigators 
recommended a SBP target between 120 and 130 mmHg, in conjunction with 
blockade of the renin-angiotensin system, in patients with Type 2 diabetic 
nephropathy, although others have urged caution in lowering the diastolic 
pressure below 60mmHg as there exists an increased risk of cardiac events, 
particularly in those with coronary artery disease. The relative risk of the renal 
endpoint (doubling of serum creatinine) in relation to achieved systolic blood 
pressure is illustrated in Figure 8.
The choice of drug therapy to achieve reductions in blood pressure will be 
discussed in greater detail in the section on prevention.
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Figure 8: Relative risk of doubling of serum creatinine with achieved 
systolic blood pressure
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Pohl M, Blumenthal S, Cordonnier D, De Alvaro F, DeFerrari G, Eisner G, at at. Independent and 
Additive Impact of Blood Pressure Control and Angiotensin II Receptor Blockade on Renal Outcomes in 
the Irhesartan Diabetic Nephropathy Trial: Clinical Implications and Limitations. Journal of the American 
Journal Society of Nephrology. 2005; 16::3027-37
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1.6.3 Obesity and the development of cardiovascular disease and
nephropathy
Obesity is a chronic metabolic disorder associated with cardiovascular 
disease and increased morbidity and mortality. Alterations in cardiac structure 
and function occur as adipose tissue accumulates both with or without the 
presence of hypertension. As a result of the metabolic needs of this excess 
tissue, circulating blood volume, plasma volume, and cardiac output all 
increase. The increase in blood volume in turn increases venous return to the 
ventricles, eventually producing dilatation and left ventricular hypertrophy. 
Systemic hypertension, pulmonary hypertension (left ventricular failure, 
chronic hypoxia) and CHD all occur with disproportionately high frequency in 
obese individuals and may cause or contribute to alterations in cardiac 
structure and function. There is also an increased risk of sudden cardiac 
death in obesity [39].
The benefits of weight reduction on the cardiovascular system have been well 
documented and include
• Decreased blood volume
• Decreased cardiac output
• Decreased left ventricular mass
Adapted from Poirier et al [39].
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It has been shown that a high body mass index (BMI) is associated with an 
increased incidence of nephropathy [40] [41] and weight loss may reduce 
proteinuria and improve kidney function [42] [43] . However the effect of 
obesity in these studies has not been demonstrated independently of 
glycaemic control.
It is evident however from all of these studies detailed above that the 
development of diabetic nephropathy is multifactorial and that currently none 
can be singled out as being the most important in the assessment of an 
individual’s risk of developing nephropathy.
1.6.4 Smoking and the development of cardiovascular disease and 
nephropathy
Cigarette smoking increases all-cause and cardiovascular mortality [44] [45] 
In the study by Qiao et al [44], the adjusted hazard ratio for 35 year all-cause 
and cardiovascular mortality was 1.62 and 1.63, respectively for current 
smokers compared to nonsmokers. In addition, those who persisted in 
smoking cessation had no increased risk of death compared to nonsmokers
Studies in individuals with Type 2 diabetes have highlighted that there is a 
higher incidence of smoking amongst the patient group with microalbuminuria 
and that for smokers, the progression from micro to macro albuminuria and 
the time from macroalbuminuria to End Stage Renal Disease and the time 
from End stage Renal Disease to death is shortened [46].
Studies have shown that cigarette smoking causes a decrease in GFR in 
diabetic patients with normal or near-normal renal function, independent of
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confounding factors including severity of proteinuria. The latter finding 
suggests a mechanism independent of glomerular damage [47].
1.6.5 Albuminuria and the development of cardiovascular disease and 
nephropathy
Microalbuminuria has been associated with increased cardiovascular mortality 
in populations of both diabetic and nondiabetic subjects [48] [49] [50]. It has 
also been used as a marker of cardiovascular disease and it has been 
hypothesised that microalbuminuria is a marker of generalised endothelial 
dysfunction.
In survivors of myocardial infarction, both albuminuria and the transvascular 
escape rate of albumin are increased [51]. Albuminuria has also been shown 
to predict the severity of atherosclerosis [52], [53].
The relative contribution of underlying vascular disease as opposed to 
diabetic nephropathy towards albuminuria is not clear. However, there is 
evidence to suggest that microalbuminuria is an indicator of both micro- and 
macrovascular disease.
In general, proteinuria is regarded as a marker of damage to the glomerulus 
but recent studies have shown that it may also contribute to renal and 
cardiovascular dysfunction in its own right. In animal models, proteinuria has 
been linked to increased interstitial inflammation [54] while Parving and 
colleagues [55] showed that rates of decline of GFR were double in patients 
with the highest rates of microalbuminuria in comparison to that of those with 
the lowest rates of albumin excretion. Data from some studies suggest that 
progression of renal disease is not related to the level of proteinuria but rather
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to the underlying degree of renal injury and this has led to the assertion that 
this is a self -fulfilling hypothesis, in that those with the most severe renal 
disease are most likely to have the worst proteinuria and the most precipitous 
decline in renal function [56].
Data from de Zeeuw and his colleagues has shown that the short-term- 
induced antiproteinuric effect of ACE Inhibitors and /or Angiotensin Receptor 
Blockers appears to predict the long-term cardiovascular and renal protection 
in that; the more albuminuria is lowered, the more that the individual is 
protected. The authors state that these data suggest that albumin is not only a 
risk marker for cardiovascular and or renal disease, but it may also be a 
useful target for therapy [57]. In addition, further studies have demonstrated 
that across all categories of Systolic Blood Pressure change, a progressively 
lower ESRD hazard ratio was observed with a larger albuminuria reduction and 
a lower residual level of albuminuria was also associated with lower ESRD 
risk [58]. In microalbuminuric subjects, treatment with fosinopril had a 
significant effect on urinary albumin excretion. In addition, fosinopril treatment 
was associated with a trend in reducing cardiovascular events [59].
Daily aspirin intake reduced vascular events by about 25 percent in patients 
who had previous myocardial infarction, stroke, transient ischemic attack, or 
cardiovascular disease; patients with diabetes had risk reductions comparable 
to those of nondiabetic patients [60].
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1.6.6 Lipids and the development of cardiovascular disease and
nephropathy
Dyslipidaemia is part of the metabolic derangement present in Type 2 
diabetes. There is a body of evidence that supports the hypothesis that links 
cardiovascular risk to elevated levels of serum lipids. In addition, it has now 
been documented that an elevated level of cholesterol is an identifiable factor 
in the loss of renal function [61]. The treatment of hyperlipidemia has a well- 
established role in reducing cardiovascular endpoints in patients with diabetes 
with most data being available for the statins. The Heart Protection Study 
included 5963 patients with diabetes who were prospectively randomized to 
treatment with simvastatin or placebo [62]. Active treatment was associated 
with a 27% reduction in coronary events. In the trial as a whole, the benefit of 
statin therapy for reducing cardiovascular risk was independent of the 
baseline low-density lipoprotein (LDL) cholesterol level. In the Collaborative 
Atorvastatin Diabetes Study, 2838 patients with type 2 diabetes age 40-75 
years were randomized to placebo or treatment with atorvastatin 10 mg daily 
[63] Although the median duration of follow-up in this trial was short at 3.9 
years, treatment with atorvastatin reduced acute coronary heart disease 
events by 36%, coronary revascularizations by 31%, stroke by 48%, and 
overall death rate by 27%. Other studies have reported similar benefits 
including that of Tonelli and colleagues [64] who reported that Pravastatin was 
of benefit in proteinuric renal disease .
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1.7 Diabetic Nephropathy what is it?
The involvement of the kidney in the consequences of diabetes is 
characterised firstly by glomerular hyperfiltration without the presence of 
albumin in the urine or raised blood pressure. Between five to fifteen years 
post diabetes diagnosis a proportion of patients will excrete levels of albumin 
in their urine of between 30 to 300 milligrams in 24 hours (microalbuminuria). 
This ‘incipient nephropathy’ is allied to a normal Glomerular Filtration Rate 
(GFR). Within a variable time frame (usually 10 to 15 years post diagnosis), 
overt nephropathy develops and is illustrated in Figure 9. Overt nephropathy 
is characterised by increasing albumin excretion in the urine, increasing blood 
pressure and a decrease in GFR. Studies have shown that after ten years of 
follow up, the risk of diabetic nephropathy was 29 times greater in patients 
with Type 2 Diabetes Mellitus with urinary albumin excretion levels > 
10pg/minute. Although microalbuminuria has been considered a risk factor 
for macro albuminuria, not all patients progress to this stage and it is believed 
that between 20-30% revert to a normoalbuminuria state, 40% progress to 
proteinuria and renal failure and 30% have persistent microalbuminuria.
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Figure 9: Course of Diabetic Nephropathy
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1.8 Association between cardiovascular disease and diabetic
nephropathy
The development of nephropathy in patients with Type 2 diabetes, reflects 
vascular dysfunction elsewhere in the body. As described previously, 
albuminuria is the first clinical indicator of nephropathy and increases the risk 
of cardiovascular events independently of traditional risk factors [65] [66].
A number of comorbidities result from or are exacerbated by, damage to the 
kidney, for example hypertension, anaemia and dyslipidaemia. These 
comorbidities occur more frequently, earlier in the disease process and with 
greater severity in the nephropathy associated with diabetes than in kidney 
disease due to other causes [54] [67] [68]. The nature of these comorbidities 
mean that most individuals with diabetes who develop kidney disease will die 
from cardiovascular disease before they require dialysis [69]. Data from the 
Heart Outcomes Prevention Evaluation (HOPE) showed that the risk of major 
cardiovascular events in individuals, both with and without diabetes, increases 
at levels of albuminuria below the current threshold for microalbuminuria [70]. 
Studies have also shown that the risk of cardiovascular events rise with 
increasing levels of urinary albumin excretion [71]
The influence of kidney disease on cardiovascular disease is due to many 
interrelated factors for example; by the time the kidney is affected by vascular 
disease the disease process itself is severe and widespread in the body. 
Endothelial dysfunction, which is a component of atherosclerosis and occurs 
in the general circulation as well as the glomerular microcirculation, is
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indicated by the presence of albuminuria. Individuals with Type 2 diabetes and 
albuminuria are at increased risk of cardiovascular disease [65] [66].
1.9 Pathological changes in the kidney
Renal pathology has been less well studied in Type 2 patients than in Type 1 
patients. There has been some controversy associated with reports that there 
is a high incidence of non diabetic renal lesions in biopsies from Type 2 
diabetic patients [72], however it is felt that this may represent selection bias 
(more atypical cases) as this finding has not been replicated in other studies. 
There is no doubt that the lesions found in biopsies of Type 2 patients are 
more heterogeneous than those in Type 1 patients [73]. In general, it appears 
that a substantial proportion of type 2 patients have tubelo-interstitial disease 
and vascular injury which is out of proportion to their glomerulopathy [74], 
On examination of renal biopsy, there is a consensus that the main findings 
are:
• Thickening of the glomerular basement membrane
• Renal Hypertrophy
• Mesangial matrix expansion
• Hyalinisation of arterioles.
The appearance of renal disease in patients with Type 2 diabetes may be due 
to other causes than diabetic nephropathy. The incidence of non diabetic 
renal disease in Type 2 patients has been reported to be as high as 30 
percent but a review by Olsen et al [75] has suggested that the variability in 
the rate of non-diabetic disease may be due to selection bias.
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1.10 Prevention
Clinical research studies have identified areas of diabetic care that can be 
used to modify the progression of patients with Type 2 diabetes to renal 
failure. Strategies have been developed which will be examined in more detail 
in subsequent chapters of this thesis but they can be broadly divided into 
three distinct areas.
1.10.1 Primary Prevention
Primary prevention is described as strategies applied to all diabetic patients, 
at risk of developing renal disease, to prevent the development of diabetic 
nephropathy. It has been demonstrated in Type 1 diabetes that intensive 
control of blood glucose levels reduce the proportion of patients developing 
diabetic nephropathy. The Diabetes Control and Complications Study [23] 
was designed to investigate whether Intensive Therapy (IT) when compared 
to Conventional Therapy (CT) would affect the risk of onset and progression of 
complications. The risks of the microvascular complications over the average 
of 6.5 years of follow-up were reduced by 26-63% with intensive versus 
conventional therapy. The IT group achieved a median HbAic throughout the 
study of 7.2% vs. 9.1% in the CT group (p<0.001). Early renal damage, the 
appearance of microalbuminuria (defined as AER > 40 mg/24 hours) was 
reduced by 60%. In addition, clinically significant renal damage, (defined as 
Albumin Excretion Rate (AER) of > 300 mg/24 hours) was reduced by 54%.
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In patients with Type 2 diabetes, the United Kingdom Prospective Diabetes
Study (UKPDS) [21] reported a relative risk of 0.8 for the intensively controlled
group when compared with those randomised to conventional control.
In addition, a study by Ravid et al demonstrated a decrease in urinary 
albumin with an ACE inhibitor and therefore, in the risk of development of 
diabetic nephropathy that was independent of any effect on blood pressure 
[76].
Recent studies have also suggested that lower is better in terms of blood 
pressure levels and confers increased benefit even when reduced into the 
normotensive range. Pohl and his colleagues have demonstrated that 
progressive lowering of systolic blood pressure to 120 mmHg was associated 
with improved renal and patient survival, an effect which was independent of 
baseline renal function. No relationship could be demonstrated in this study 
between diastolic blood pressure and renal outcomes [77]
1.10.2 Secondary Prevention
Secondary prevention is targeted at patients who already have 
microalbuminuria and aims to slow progression to overt nephropathy
Early treatment of hypertension is very important in diabetic patients both to 
prevent cardiovascular disease and to minimise progression of renal disease 
[78]. Amongst Type 2 diabetics, the benefit of strict blood pressure control
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may be as great or greater than the benefit conferred by strict glycaemic
control [21].
Since hypertension places diabetic patients at very high risk of cardiovascular 
complications, it has been recommended that all diabetics with blood 
pressures above 140/90 mmHg should start anti hypertensive drug therapy 
immediately [79], [80]. The evidence is unequivocal that intensive drug 
therapy is protective [21], [78], [81] and therefore, all diabetics should have 
their blood pressure reduced to below 130/80 mm of mercury as detailed in 
recommendations adapted from the Seventh Report of the Joint National 
Committee on Prevention, Detection, Evaluation, and Treatment of High Blood 
Pressure and illustrated in Figure 10 [82].
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Figure 10: Classification and management of blood pressure for adults aged 18 years or older
danHlcatioii Systolic (mm Hg) Diastolic (mmHg) Initial Drug Therapy
Without compelling indication With compelling indication
Normal <120 and <80
Prehypertension 120-139 or 80-89 No antihypertensive drug indicated Drug(s) for the compelling indicationsA
Stage 1 hypertension 140-159 and 90-99 Thiazide-type diuretics for most; 
may consider ACE inhibitor, ARB, 
beta blocker, CCB, or combination
Drug(s) for the compelling indications; 
other anti-hypertensive drugs (diuretics, 
ACE inhibitor, ARB, beta blocker, CCB) as 
needed
Stage 2 hypertension 2 160 and > 100 2-drug combination for most (usually 
thiazide-type diuretic and ACE 
inhibitor or ARB or beta blocker or 
CCB)0
Drug(s) for the compelling indications, 
other antihypertensive drugs (diuretics, 
ACE inhibitor, ARB, beta blocker, CCB) as 
needed
ACE: angiotensin-converting enzyme; ARB: angiotensin-receptor blocker BP. blood pressure; CCB: calcium channel blocker.
* Treatment determined by highest BP category.
ATreat patients with chronic kidney disease or diabetes to BP goal of less than 130/80 mmHg. Other compelling indications include disorders such as heart failure, post-myocardial infarction, and 
atrial fibrillation in which particular antihypertensive drugs are warranted independent of BP.
I^nitial combined therapy should be used cautiously in those at risk for orthostatic hypotension.
Adapted from The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High 
Blood Pressure, Hypertension 2003,42,1206-1252.
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1.10.3 Tertiary Prevention
There is little evidence to suggest that patients who have developed overt 
nephropathy, benefit, in terms of disease progression, from tight glycaemic 
control in this stage of the disease process, although poor glycaemic control 
has been shown to be associated with progression and predict a poor 
outcome on dialysis. By contrast, modification of life style factors and drug 
therapy in the long term control of hypertension has been shown to delay 
progression of renal disease
1.10.3.1 Evidence underpinning choices of drug therapy in the 
management of hypertension in tertiary prevention.
Initial treatment plans should be tailored to lifestyle changes including weight 
reduction, introduction of healthy diet, exercise plans and smoking cessation. 
The choice of agents to control blood pressure is based upon their efficacy in 
two areas, firstly their ability to slow the progression of renal disease and 
secondly their ability to prevent cardiovascular morbidity and mortality. There 
is extensive evidence of the effect of both Angiotensin Converting Enzyme 
(ACEi) inhibitors and Angiotensin Receptor Blocker (ARB) in slowing the 
progression of renal disease and although this will be dealt with in some depth 
in Chapter 4, it is important to highlight the main evidence.
Much of the information available on the potential of ACE inhibitors to slow the 
progression of nephropathy has been carried out in Type 1 Diabetes Mellitus
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although the small number of studies in Type 2 diabetes appear to show a 
similar effect. Currently more data are available in Type 2 diabetes on the 
effect of ARBs. In the Irbesartan Diabetic Nephropathy trial, over 1700 
patients with type 2 diabetes and hypertension and nephropathy were 
assigned randomly to treatment and the results showed a reduction for the 
patients on an ARB of 23 (versus amlodipine) and 20 per cent (versus 
placebo) in the combined endpoint of (doubling in serum creatinine, all cause 
mortality and cardiovascular events). The study also showed a threshold of 
120mg Hg for the decrease in cardiovascular death and heart failure and 
doubling of serum creatinine or progression to end stage renal disease. [77, 
83],
In clinical practice, therapy is normally initiated with an ACE inhibitor or an 
ARB. This is largely based upon the evidence that such agents protect against 
the development of progressive nephropathy. If the blood pressure is not 
controlled by an ACEi or ARB alone the addition of a diuretic is 
recommended. A thiazide is added if the goal blood pressure is not attained 
with an ACEi/ARB alone which has been administered at the maximally 
recommended dose.
The K/DOQI clinical practice guidelines recommend that the goal for blood 
pressure for patients with reduced renal function should be to 130/80 mmHg, 
[84]. There is evidence suggesting that an even lower systolic pressure may 
be more effective in slowing progressive renal disease in patients with a spot 
urine total protein-to-creatinine ratio ^1000 mg/g [85].
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As described in this chapter, the basis for modification of the progression of 
diabetic nephropathy and lowering of cardiovascular risk should be centered 
on treatment of known and modifiable risk factors for both comorbidities. In 
this thesis, the focus of study will encompass the
• Accurate and timely screening for the presence of microalbuminuria, as 
identification underpins the required interventions.
• Treatment and management of blood pressure
• Investigation of the potential genesis of anaemia in diabetic 
nephropathy given the precipitous reported nature of the development 
of anaemia in diabetic nephropathy and the effect of anaemia in left 
ventricular hypertrophy and increased cardiovascular risk.
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Chapter 2
Methods
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2. Study profiles
Three studies in diabetic nephropathy comprise the totality of this thesis;
a) Study 1, in two parts, undertook screening and assessment of Diabetic 
Nephropathy in the Diabetic Clinic,
b) Study 2 -  Optimisation of risk factor management of the patient cohort 
identified in Study 1, for 12 months and
c) Study 3 -  An exploration of haematolological and haematinic parameters in 
a selected subgroup of the original cohort.
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2.1 Study One
2.1.1 Screening of patients with Diabetic Nephropathy in the Diabetic 
Clinic
All patients enrolled into Study 1 attended the diabetic clinic led by a single 
diabetologist based at a teaching hospital. Patients in the initial phase 
comprised all consecutive patients seen in the diabetic clinic over a 6month 
period. Data (patient notes and laboratory records) from this initial patient 
cohort were evaluated to ascertain the number of patients with diabetic 
nephropathy and whether this diagnosis was available to the physician at 
clinic attendance. The diagnosis of diabetic nephropathy used by the clinic 
prior to any intervention used a standard screening protocol based on the 
formal quantification of microalbuminuria on three separate occasions.
Incipient nephropathy was defined as persistent microalbuminuria ranging 
from 20-200mg/l hours in at least three consecutive urinary samples. Overt 
nephropathy was defined as albuminuria greater than 200mg/24h. Patients 
with impaired renal function in the absence of proteinuria, patients with 
microscopic haematuria and patients with known multi-system disease were 
excluded from this study.
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2.1.2: Assessment of patients with Diabetic Nephropathy in the Diabetic 
Clinic by a dedicated nurse specialist
In the second phase of this part of the study, screening for diabetic 
nephropathy was co-ordinated and performed by a newly appointed dedicated 
nurse specialist who altered the method for screening. Prospective 
quantification of albumin: creatinine ratio on a random single urine sample 
collected at the time of the clinic visit prior to seeing the physician, using a 
CLINITEK 50 Analyzer (Bayer Corporation, Elkart, U.S.A.) was carried out for 
an 8 month period. In all patients with elevated albumin: creatinine ratios 
(men>2.5mg/mmol, women >3.5mg/mmol), subsequently albuminuria was 
confirmed by timed urine collection following a discussion with the nurse 
specialist regarding the probable diagnosis and the benefit of early 
identification and treatment.
Out-patient patient assessment included demographic data, serum creatinine, 
HbAic, and cholesterol (Figure 11). Blood pressure was measured with an 
calibrated automatic digital blood pressure monitor, after 5-10 min sitting at 
the clinic using an algorithm (Figure 12) to aid decision making. Where 
necessary, ambulatory Blood Pressure was measured using Spacelabs 
ambulatory blood pressure system In addition prescribed medication was 
assessed and in particular the use of Angiotensin Converting Enzyme 
inhibitors, Angiotensin Receptor Blockers, aspirin and cholesterol lowering 
medication noted.
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2.2 Study 2: Optimisation of risk factor management during twelve 
month follow up of cohort identified in Study 1
Study Two consisted of follow up of a patient cohort with diabetic nephropathy 
who had their management optimised over a twelve month period and 
treatment intervention instigated and recorded by a dedicated nurse specialist 
using both primary and secondary care to effect and maximise change.
Clinic blood pressure was measured with an automated digital blood pressure 
monitor (Omron Healthcare UK, Henfield, West Sussex, UK) after a 5-minute 
seated rest. An algorithm was designed to assist and standardise the 
identification of all patients with sub optimally controlled blood pressure 
(Figure 12). The nurse then ensured that all clinic medical staff were informed 
that these patients needed treatment modification and made suggestions on 
optimal treatment using evidence based algorithms (Figures 13 and 14).
All patients with diabetic nephropathy (microalbuminuria) and blood pressure 
recordings at or below target had their drug treatment scrutinised by the 
specialist nurse to ensure ACEi and /or ARBs were being prescribed, even in 
the absence of hypertension. An algorithm was used for commencing ACE 
inhibition in normotensive nephropaths, not already prescribed these drugs, to 
ensure renal function and blood pressure were monitored appropriately 
(Figure 13).
A treatment intensification algorithm was provided for the nurse specialist to 
use for patients with diabetic nephropathy and blood pressure recordings 
above target (Figure 14). This was designed to maximise the use of ACE 
inhibitors and/or ARBs as first line management, with the addition of
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Indapamide to act synergistically if blood pressure was not optimally 
controlled. Although the intensification policy is similar to that suggested by 
the British Hypertension Society published guidelines it is more prescriptive 
taking account of the high co-morbidity rates associated with a diabetic patient 
population.
Follow up
All patients with blood pressure measurement at or below target were 
allocated to routine follow up care comprising annual follow up in the diabetic 
clinic.
For patients above target, where possible, treatment changes were initiated in 
the diabetic clinic. However, in patients where this was not possible, the link 
between the nurse specialist and the Primary Care team was utilised to bring 
about treatment change.
In addition to the Clinical Nurse Specialist and the Primary Care Team, a 
Consultant Nephrologist was available to offer additional advice about 
treatment changes or difficult management decisions. Follow up was arranged 
with primary care and information from the follow up visits was fed-back to the 
Clinic Specialist Nurse. Once blood pressure was at target the patients were 
then seen 3 monthly by the Practice Nurse.
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2.3 Study 3: Development of anaemia in individuals with type 2 Diabetes 
Mellitus
In this study on the development of anaemia, a sub group of individuals were 
identified from the Research Clinic of the Academic Diabetes Research Unit, 
Llandough Hospital, Cardiff, where they were under long term follow up. All 
patients had been followed up for a minimum of five years. Sixty two (62) 
patients gave written informed consent. All recruited patients had Type 2 
diabetes and had undergone exhaustive yearly health checks, including 
formal isotope measurement of Glomerular Filtration Rate (GFR) and 
assessment of proteinuria.
Data collection was undertaken both prospectively during annual review and 
retrospectively from a search of medical records and electronic patient 
haematology results.
For research purposes serum ferritin, serum erythropoietin levels and 
reticulocytes were measured at annual diabetic review, in addition to routine 
parameters including haemoglobin, haematocrit, HbAic, and Glomerular 
Filtratation Rate. In addition retrospective haematological results were 
collected from the patient records, for the period prior to recruitment in order 
to examine the effect of time since diabetes diagnosis on haematological 
parameters.
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2.4 Statistical Analysis
Statistical analysis was undertaken using SPSS for Windows Version 14.0. All 
parameters were tested for distribution and as appropriate, parametric and 
non parametric analyses were undertaken.
For variables with normal distribution, values were reported as Mean ± 
(Standard Error of Mean) and analysed using paired or unpaired T-tests as 
appropriate. For variables which were not normally distributed, values were 
reported as median (Inter Quartile Range) and non parametric statistical 
analysis were used, including Kruskal Wallis tests for k independent variables 
and Mann-Whitney tests for two independent variables. Where appropriate, 
Chi-squared analysis was undertaken. The criterion for statistical significance 
in all cases was p<0.05.
Graphical representation of all continuous variables were made using ‘box 
and whisker’ plots with the upper and lower limits of each box representing the 
75th and 25th centile respectively and the line within the box indicating the 
median value. The lowest and highest values in each case were represented 
by the ‘whiskers’. Outliers, (values greater than two standard deviations from 
the mean) were represented by open circles and extremes (values greater 
than three standard deviations form the mean) by an asterisk.
In addition, histograms and frequency charts were used, where appropriate, 
including a ‘normal curve’.
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Figure 11: Diabetic Nephropathy  -  Screening
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Figure 12
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Figure 13
ACE inhibitors and normotensive nephropaths
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53
Figure 14
BP treatment algorithm
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Chapter 3
Identification and Management of Diabetic Nephropathy in the Diabetic 
Clinic
55
3.1 Introduction
Studies performed to date focusing on referral patterns and management of 
diabetic nephropathy in nephrology clinics have highlighted sub-optimal care 
and late referral [86], [87]. It is clear however, that appropriate 
implementation of treatment guidelines following referral to specialised clinics, 
either diabetic-renal clinics [86] or nephrology clinics [87] , slowed the 
progression of established diabetic nephropathy. The importance of early 
referral and intervention is also apparent since a retardation in the rate of 
decline in renal function may take up to 3 years [86]. It has also been shown 
that implementation of a multi-factorial approach to the diabetic patient leads 
to improvement in progression of complications other than nephropathy [78]
As highlighted in preceding chapters, for the majority of patients, screening is 
not merely undertaken to detect progressive renal disease. Only thirty to forty 
percent of diabetic patients will develop microalbuminuria and of those around 
forty percent will develop proteinuria which may progress to renal failure. For 
those without microalbuminuria, detection and modification of cardiovascular 
risk will be the most important factor in patient management. During an eight 
year follow-up study in Norway, only 38 of the 3069 people with chronic 
kidney disease with and without diabetes progressed to end stage renal 
disease. In contrast, there was a high cardiovascular mortality: 3.5, 7.4, and
10.1 deaths per 100 person years among people with a glomerular filtration 
rate 45-59, 30-44, and <30 ml/min/1.73 m2, respectively In this study, Hallan 
et al concluded from this that screening individuals with hypertension, 
diabetes mellitus, or age >55 years was the most effective strategy for the
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detection of patients with chronic kidney disease, but the risk of end stage 
renal disease among those detected was low [88].
In a recent study amongst Chinese patients, researchers found that Chinese 
type 2 diabetic patients with reduced eGFR were at high risk of developing 
cardiovascular end points and all-cause mortality, independent of albuminuria 
and metabolic control. [89]
Patients with diabetic nephropathy and reduced GFR require long term follow 
up and management and the effect of age has been underlined in a recent 
study undertaken by O’Hare and colleagues, which highlights the effect of age 
on the relationship between glomerular filtration rate and mortality [90]. 
Evidence from the PROGRESS study demonstrates the effect of reduction of 
cardiovascular risk (by lowering blood pressure) on the recurrence of 
cerebrovascular events [91].
Maximal reduction in the morbidity and mortality of patients with diabetic 
nephropathy requires early identification of ‘at risk’ individuals allowing 
instigation of appropriate management protocols known to influence renal and 
cardiac outcome.
In the current chapter, assessment has been carried out on the efficiency of 
current practice in early identification and management of diabetic 
nephropathy in terms of both renal and cardiovascular risk. In addition, 
examination has been undertaken of the impact of changing screening 
procedures and the identification of the true at risk’ population.
57
3.2 Results
3.2.1 Identification of patients with Diabetic Nephropathy in the Diabetic 
Clinic.
The initial phase of the study was used to delineate current practice, assess 
screening rates and make decisions on improvements to screening and 
management for renal and cardiovascular risk that could be undertaken in this 
patient group.
3.2.1.1 Definitions of nephropathy
Incipient nephropathy was defined as persistent microalbuminuria ranging 
from 20-200 milligrams (mg) per litre in twenty four hours in at least three 
consecutive urinary samples. Overt nephropathy was defined as albuminuria 
greater than 200mg/24hours. Patients with impaired renal function in the 
absence of proteinuria, patients with microscopic haematuria and patients with 
known multi-system disease were excluded.
3.2.1.2 Current Practice
Current practice within the diabetic clinic included blood pressure 
measurement and microalbumin screening at diagnosis and at yearly 
intervals. Results were reported to Primary Care after this appointment but no 
joint management plan for each patient was put in place and no agreed 
targets for blood pressure or re-referral to the specialist clinic were formally 
identified.
The screening for and measurement of microalbuminuria was particularly 
problematic and complex. All patients were given three (3) containers for
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collection of early morning urine samples, which were then returned to their 
General Practitioner who arranged for the samples to be sent for analysis. 
Once results were received, they were copied and sent to the specialist 
diabetic clinic were it was planned that all results were filed in the patient 
medical notes.
3.2.1.3 Demographics of Patient Cohort
In the initial patient cohort, a total of six hundred and forty four (644) patient 
notes and laboratory records were evaluated. Microalbuminuria results were 
available for four hundred and eighty five (485) patients (75%). Of these, 115 
patients were identified as meeting the criteria for a diagnosis of diabetic 
nephropathy giving an observed prevalence of diabetic nephropathy of 17%. 
The overwhelming majority of these (90.6%) were type 2 diabetics. 
Demographic data for the identified nephropaths is shown in Table 1. Of 
those patients identified with diabetic nephropathy, 72.6% had incipient 
nephropathy, 27.4% had overt nephropathy and of the latter group 78.6% had 
elevated serum creatinine levels. The mean serum creatinine for incipient and 
overt nephropathy group was 91(76-145) pmol/l, median (IQR) and 112 (109- 
141)) pmol/l, median (IQR) respectively.
Of the 115 known patients with nephropathy, results of urinary microalbumin 
or proteinuria quantification were available for the physician at the time of the 
out-patient consultation in only 53% of the patient case records. The 
remaining patients with nephropathy could only be identified from the patients’ 
laboratory records and were not available to the physician at the time of 
consultation.
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Due to resource constraints, it was not possible to undertake a more detailed 
review of the patient characteristics of the group but the fact that only half of 
the patients had microalbumin screening results available at the time of 
physician review gave cause for concern.
The process surrounding the original screening at diabetic clinic was 
cumbersome and even with very good patient compliance could take a 
considerable length of time. It involved the patient attending the diabetic clinic 
for review and being given three sample bottles to collect three consecutive 
early morning urine samples whilst they were there. The samples had to be 
delivered, by the patient, to their Primary Care surgery who would then send 
the samples on to the laboratory for testing. Results would then be returned to 
the surgery that might or might not forward the result to the diabetic clinic. 
Patients sent their samples at varying times, post appointment, some not 
remembering until they were due to attend for their follow up appointment 12 
months later. Positive review of returned microalbumin results was undertaken 
by the administrative staff of the specialist centre who ensured that results 
were reviewed by a consultant but there was no formalised system of follow 
up for those who did not return their samples.
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3.2.2 Assessment of management of patients with diabetic nephropathy 
in the Diabetic Clinic
From the initial study, twenty five (25) percent of patients were not screened 
and of those that were screened, forty seven (47) percent of results were not 
available at the time of physician consultation. In the second phase of the 
study, screening for diabetic nephropathy was co-ordinated and performed by 
a newly appointed dedicated nurse specialist. Previous studies have 
demonstrated the efficacy of quantification of the ratio of urinary albumin to 
creatinine in a random single voided urine sample as a reproducible
alternative to the formal quantification of urinary protein loss [92]. In addition
to appointment of the nurse specialist, during the second phase of the study, 
screening practice for diabetic nephropathy was altered. Prospective
quantification of albumin: creatinine ratio on a random single urine sample
collected at the time of the clinic visit prior to seeing the physician, using a 
CLINITEK 50 Analyzer was carried out on patients attending the diabetic clinic 
over a further eight (8) month period. In all patients with elevated albumin to 
creatinine ratios, albuminuria was confirmed by formal quantification following 
a discussion between the nurse specialist and the patient regarding the 
probable diagnosis and the benefits of early identification and treatment.
For all patients, at the time of out-patient visit, assessment included 
demographic data, serum creatinine, HbAic, cholesterol, haemoglobin and 
ferritin. Blood pressure measurement was standardised using an automated 
digital blood pressure monitor after five to ten minutes sitting at the clinic. In 
addition, prescribed medication was assessed and in particular the use of
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Angiotensin Enzyme Converting Enzyme inhibitors, All receptor antagonists, 
aspirin and cholesterol lowering medication noted.
The role of the dedicated nurse was extended to ensure that compliance with 
formal quantification of microalbumin levels in those who were positive on 
sampling was thorough and achieved total compliance of one hundred (100) 
percent.
In this patient cohort, 174 patients were identified as having diabetic 
nephropathy giving a prevalence of nephropathy of 20%, suggesting that 
prospective screening increased the number of diabetic nephropaths in the 
clinic population by 17.6%. Of these 174 patients, 134 had been identified 
previously as having diabetic nephropathy, by the existing screening practice, 
on the basis of positive urine albumin quantification. This was recorded either 
in the patients’ records or in the laboratory records. Forty (40) patients 
however had no previous record of microalbumin quantification, and were 
therefore newly identified as having diabetic nephropathy from prospective 
screening.
Comparison of the demographic data of the known diabetic nephropathy 
patients identified in Phase I and those in Phase II revealed no differences in 
patient characteristics (Table 2) (age, sex, duration of diabetes, HbAic, Typel 
vs. Type II, incipient vs. overt nephropathy).
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Table 2: Characteristics of patients identified by standard screening in 
both the retrospective and prospective cohorts
Phase I- known 
nephropaths n=115
Phase li- known 
nephropaths n=134
Age (years) 65 (55-71) 66 (58-72)
Gender (male:female) 62.1%:37.9% 63%: 37%
% Type 2 diabetes 90.6% 95.1%
HbAic (units) 8.0 (7-9.7) 8.2 (7.1-9.4)
Duration of diabetes 
(months)
108 (60-192) 84 (48-156)
Incipient nephropathy 72.6% 75.9%
Overt nephropathy 27.4% 24.1%
Raised serum creatinine 
in those with overt 
nephropathy
78.6%% 50.0%
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The prevalence of known patients with diabetic nephropathy in the 
retrospective and prospective cohorts was equivalent at 16.9% and 15.5 % 
respectively. The addition of the previously unknown patient cohort added an 
additional 4% giving a true prevalence of 19.5% as illustrated in Figure 15. As 
illustrated in Figure 16, the characteristics of patients in all three groups in 
terms of the proportion of Type 2 diabetics and the prevalence of overt 
nephropathy were similar.
Figure 15: Presumed and true prevalence of diabetic nephropathy
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Figure 16: Comparison of background characteristics of patient groups
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Comparison of patient characteristics of all the known patients with 
nephropathy and those newly identified in Phase II is shown in Table 3. The 
serum creatinine for incipient and overt nephropathy in the newly identified 
group were 105 (87-162) pmol/l, median (IQR), and 102(83-159) pmol/l, 
median (IQR), respectively. There was no difference in age, sex, HbAic, 
duration of diabetes or incidence of incipient versus overt nephropathy. 
These data would suggest that these patients represent a cohort of patients 
truly missed by the standard practice in this clinic.
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Table 3: Patient characteristics of diabetic nephropaths identified by 
standard screening and those newly identified nephropaths identified by 
nurse led prospective screening based on random measurement of 
urinary albumin to creatinine ratios.
AH known nephropaths 
n*249
Newly identified 
nephropaths n«40
Age (years) 66 (58-73) 66 (58-75)
Sex (male:female) 37.5% : 62.5% 45.7% : 54.3%
% type II diabetes 93.3% 80.%
Hbaic 8.0 (7.0-9.5) 8.5(7.8-10.2)
Duration of diabetes 
(months)
90 (60-168) 120 (48-180)
Incipient nephropathy 74.% 77.4%
Overt nephropathy 25.5% 22.6%
Overt nephropathy and 
raised serum creatinine
65.4% 50%
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3.3 Risk factor management in known and newly identified nephropaths
Having identified a cohort of patients with diabetic nephropathy, the 
management of this patient group was examined and compared with the 
recommendations enshrined in the National Institute of Clinical Excellence 
guidelines for the management of renal disease in diabetes and outlined in 
Table 4 [93]
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Table 4: NICE Guidelines: Renal care for all people with type 2 diabetes
The NICE guidelines, published in 2002 and due for review in 2005 (in progress) state that
Recall and annual review for people with type 2 diabetes.
Review complications and risk factors at diagnosis and at least annually 
Measure urinary albumin: creatinine ratio or albumin concentration annually.
-  Use a first morning urine sample where practicable and a laboratory or near-patient test 
specifically for microalbuminuria.
If microalbuminuria or proteinuria is present, repeat twice more (within 1 month 
where possible).
Measure serum creatinine annually and classify as: lower risk (absence of microalbuminuria 
or proteinuria), or higher risk.
Care for people with lower-risk albumin excretion
• Maintain good blood glucose control (preferably HbA1c below 6 .5-7 .5% , according to the 
individual’s target)
• Maintain good blood pressure control (target blood pressure at or below 140/80  
mmHg).
Care for people with higher-risk urine albumin excretion
If retinopathy is not present, look for a non-diabetes-related cause of renal disease (full 
history and examination, urinalysis, renal ultrasound, other investigations as appropriate) 
Ensure good blood glucose control (HbA1c below 6 .5-7 .5% , according to the 
individual’s target).
Measure, assess and manage cardiovascular risk factors aggressively including the 
maintenance of blood pressure below 135/75 mmHg Begin therapy with an appropriate ACE  
inhibitor for cardiovascular/renal protection. Combination therapy is likely to be necessary for 
most patients.
Measure urine albumin and serum creatinine levels at each visit.
Refer for specialist/nephrological opinion if serum creatinine greater than 150 pmol/l
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3.4 Blood pressure control
Overall levels of systolic and diastolic pressure in the total identified cohort of 
patients with diabetic nephropathy are illustrated in Figures 17 and 18.
The number of patients with systolic blood pressure levels at or below target 
was 66 or 27.6 % of the total population. The distribution of systolic blood 
pressure levels, median (Inter Quartile Range) were 128 (120-130) mmHg in 
the group at target and 155.6(142-173.5) mmHg in those who were not at 
target and are illustrated in Figure 19.
The number of patients with diastolic blood pressure levels at or below target 
was 82 or 34.3% of total. Similar differences are seen in the levels (Median 
(IQR)) of diastolic blood pressure in those at target 68(62-71) mmHg and not 
at target 83(80-90) mmHg and are illustrated in Figure 20.
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Figure 17: Systolic Blood Pressure
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Figure 18: Histogram of Diastolic Blood Pressure
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Figure 19: Systolic Blood Pressure levels of those at target and not at
target
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Figure 20: Diastolic Blood Pressure levels of those at target and not at
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Number of Prescribed Antihypertensive Agents
The number of antihypertensive agents that each patient had been prescribed 
was noted including Angiotensin Converting Enzyme Inhibitors (ACEI); 
Angiotensin Receptor Blockers (ARB); Calcium Channel Blockers; Beta 
Blockers; Centrally Acting Drugs; Diuretics and the total number of 
antihypertensive medications were counted and are shown graphically in 
Figure 21. As can be seen, there were numbers of patients meeting and not 
meeting targets for blood pressure who were and were not prescribed 
antihypertensive agents. No statistically significant difference could be 
demonstrated between those meeting and not meeting guidelines in terms of 
the number of prescribed antihypertensives.
Figure 21: Total number of AntiHypertensive agents (AH) prescribed
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Systolic Blood Pressure in those who were and were not prescribed 
ACEi and/or ARBs
The difference in systolic blood pressure levels in those who were and were 
not prescribed ACEI-lnhibitors or AR-Blockers are illustrated in Figure 22 and 
showed a statistically significant difference, p=0.003, using Mann-Whitney 
test. No difference could be demonstrated between diastolic blood pressure 
levels.
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Figure 22: Systolic Blood Pressure of those not on treatment with ACEi 
or ARB compared with those on treatment
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Differences between known and newly diagnose diabetic nephropaths
The distribution of systolic blood pressure and diastolic blood pressures in the 
known nephropaths and the newly identified nephropaths in shown in Figure 
23. There were no statistically significant differences in the blood pressure 
recordings of patients with known and newly diagnosed nephropathy. Systolic 
blood pressure guidelines (<135 mmHg) were met by 31% of all known 
nephropaths, and 26.5% of newly diagnosed nephropaths. Diastolic Blood 
Pressure guidelines (<75 mmHg) were met by 36% of all known nephropaths 
and 38% of newly diagnosed nephropaths. However the median, (25th and 
75th centile) measures of both systolic and diastolic pressures reflect the fact 
that 50% of measurements were tightly grouped -
• Known nephropaths Systolic BP 142(133-160): Diastolic BP 80(70-85)
• New nephropaths Systolic BP 149 (137-174): Diastolic BP 77.5 (70-82).
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Figure 23 Systolic (solid shapes) and Diastolic (striped shapes) blood 
pressure of known nephropaths (Phase I and II) and newly identified 
nephropaths (Phase II).
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Use of ACEI inhibitors
In the patient group of known nephropaths from Phase I and II, 63% were 
prescribed ACEi inhibitors or ARBs. Of those patients who did not meet the 
guidelines for blood pressure target of <135/75, 24% were not receiving ACEI 
inhibitors or ARBs (Table 6).
Use of ACEi inhibitors or ARBs in the newly identified nephropathy patient 
cohort from Phase II, was 48% and is illustrated in Figure 24. In this patient 
cohort, of those who did not meet the guidelines for blood pressure target of 
<135/75, 47% were receiving ACEi or ARBs.
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Table 6: Blood pressure control and use of Angiotensin inhibitors 
(ACEi)/Angiotensin Receptor Blockers (ARB) in the known and newly 
identified patients with diabetic nephropathy.
Phase II- known Phase ll-newly
nephropaths identified
n*134 nephropaths n=40
Mean SBP (mmHg) 140 140
(130-154) (133-157)
Mean DBP (mmHg) 78 80
(70-80) (70-81)
% of patients with
BP>135/75 not on 26.3 % 53.6 %
ACEi /ARBs
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Figure 24: Prescription of Angiotensin Converting Enzyme Inhibitors 
and Angiotensin Receptor Blockers in the newly diagnosed and known 
nephropaths.
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3.5 Management of hypercholesterolaemia
There was no difference in the median cholesterol, LDL, HDL cholesterol nor 
triglycerides levels between the known and newly identified nephropaths 
(Table 7). For the known nephropaths 35% had total cholesterol greater than
5.2 mmol/l, In this group statins were prescribed for only 31% of the patients. 
Similarly elevated cholesterol (total cholesterol >5.2 mmol/l) was documented 
in 37.5% of newly identified nephropaths, of whom only 9% were prescribed 
statins.
Table 7: Lipid profiles of diabetic nephropaths.
All known nephropaths 
n=249
Phase ll-newly identified 
nephropaths n=40
Cholesterol (mmol/l) 4.6 (3.9-5.0) 5.0 (4.6-5.5)
Triglycerides (mmol/l) 2.2(1.6-3.2) 2.5(1.8-3.2)
HDL cholesterol (mmol/l) 1.1 (0.9-1.3) 1.2(1.0-1.5)
LDL cholesterol (mmol/l) 2.2 (1.8-2.7) 2.6(1.9-3.0)
3.6 Use of Aspirin
Following publication of the HOT study, the clinic protocol for the treatment of 
hypertension has included prescription of low dose aspirin to hypertensive 
diabetics. Analysis of patient records and direct questioning of patients 
however demonstrated that aspirin was prescribed in only 38% of known 
nephropaths with hypertension and 43% of newly diagnosed nephropaths with 
hypertension.
83
3.7 Discussion
The ever-increasing incidence of diabetic nephropathy has major implications 
for both patient welfare and health care resources at a time when renal 
services are already struggling to cope with current demand. The ominous 
significance of renal involvement in Type I is shown by the comparison of long 
term outcome in patients with and without nephropathy. Only 10% of patients 
with proteinuria survive after 40 years of diabetes, in contrast to more than 
70% of those without proteinuria [94]. Furthermore the mortality rates for 
diabetic patients on end-stage renal failure programs is roughly twice that for 
patients with end stage renal diseases from other causes [86]. Numerous 
treatment strategies have however been identified which delay the 
progression of renal disease in diabetes. Significantly in these studies, delay 
in the progression of renal disease is also associated with improved patient 
survival [95].
With guidelines setting strict targets for the treatment of nephropathy [93] and 
increasing evidence that earlier intervention may benefit this patient group 
[96], [97], it is obvious that clear and effective implementation strategies are 
required. If successful, it is likely that this would significantly improve both the 
patient quality of life and life expectancy. Furthermore any reduction in the 
prevalence of end stage renal failure in diabetes mellitus could have a major 
impact on the economics of health care provision.
The implementation of evidence based therapeutic interventions in diabetes, 
outside the confines of a clinical trial have however proved difficult [98], One
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factor implicated in this is the late referral of diabetic patients to specialist 
renal clinics, as highlighted by the publication of Burton et al [99]. This study 
demonstrated that the majority of patients were referred at a time when 
complications of renal failure were already present and that late referral was 
associated with sub-optimal clinical management of renal disease, in 
particular a poor outcome on dialysis. What is also clear it that the transfer of 
care to specialist renal centres may delay the progression of diabetic 
nephropathy and improve patient morbidity in the forty percent of patients who 
develop renal disease [87].
Generally, data show that the translation of best practice from both clinical 
trials and published guidelines into pragmatic clinical practice is difficult and 
incomplete. One factor suggested to be important is the paucity of resources, 
especially of non-physician personnel. Many initiatives have demonstrated 
that the use of physician directed nurse led case management of patients both 
in improving the glucose management aspect of the delivery of diabetes care 
and in the aftercare of other chronic conditions [98] [100] [101] [102]. One 
study has shown that although baseline screening rates for diabetic 
nephropathy are improving in the U.S.A. the introduction of nurse care 
management can improve these rates further [102]. The results of this current 
study support these observations.
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The appointment of a nurse to co-ordinate screening had specific aims, 
namely
• To act as a resource to undertake and coordinate care
• To simplify the operationalisation of the system for microalbumin 
screening and increase patient compliance
• To act as an education resource for medical staff in secondary care, in 
particular to ensure that more junior staff were well informed and to 
highlight gaps in therapy
• With support from medical staff, to act as a resource for primary care 
physicians and nurses using seminars to disseminate best practice 
and assist in the practical aspects of improving screening
• To act as an educational resource for the patient cohort, ensuring that 
this improves returns for microalbumin screening.
Previous studies have demonstrated that the quantification of the urinary 
albumin to creatinine ratio in a random single voided urine sample is a 
reproducible alternative to the formal quantification of urinary protein loss 
[92]. Using this approach, a cohort of diabetic patients with nephropathy was 
identified, in whom the diagnosis had not been made by existing clinical 
practice, and therefore appropriate intervention could not have been initiated. 
Interestingly there were no significant differences between the nephropaths 
diagnosed by the existing protocol and the additional newly identified group of 
patients detected by the nurse led screening program. Specifically the newly 
identified group were not those with recent onset of Diabetes Mellitus but 
came from the same population as those who were known nephropaths and
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may therefore truly have been ‘missed’. The discrepancy in the assumed and 
true prevalence of diabetic nephropathy has identified numerous levels at 
which screening practice was failing to identify patients with diabetic 
nephropathy. Although screening was targeted to all patients, compliance in 
terms of return of urine samples resulted in numerous missed patients. 
Furthermore, failure of documentation, even in those in which the screening 
program did lead to a diagnosis of nephropathy, led physicians to be unaware 
of the diagnosis at the time of patient consultation.
Another factor which hampers the introduction of structured care protocols is 
patient compliance. Studies aimed at starting an intensive lipid-lowering 
strategy in patients with diabetes mellitus demonstrated the importance of 
patient perceptions of treatment benefits as only 12% of their patients 
participated in the study [103]. Nurse led initiatives in diabetes care in 
general practice, however, have shown benefit to patients in terms of clinical 
management and also significantly in patient satisfaction [101]. Following 
instigation of prospective screening, albumin: creatinine ratio was used to 
target those patients for quantification of urinary albumin excretion at the time 
of their clinic visit. To improve patient compliance, all patients with raised 
urine albumin: creatinine ratios in the random urine samples were seen by the 
designated nurse and counselled as to the importance of further urine albumin 
quantification. Furthermore, patients who failed to provide urine samples for 
formal quantification of urinary albuminuria were contacted again by the 
nurse.
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The excess morbidity and mortality in diabetic patients requiring renal 
replacement therapy is explained by high cardiovascular co-morbidity, and 
survival on dialysis is largely determined by pre-dialysis care [104] In terms of 
minimising cardiovascular risk, analysis of the UK Prospective Diabetic Study 
(UKPDS) and the diabetic sub-group of the Hypertension Optimal Treatment 
(HOT) trial has provided clear evidence that control of blood pressure reduces 
the risk of cardiovascular events [105] [80]. The targets for optimum blood 
pressure control have been decreasing steadily over the last ten years, but 
the plethora of differing targets have led to difficulties for clinicians and 
patients in keeping abreast of changes. Furthermore analysis of diabetic 
patients recruited into the Heart Outcomes Prevention Evaluation (the 
MICRO-HOPE) study suggested a specific cardio-protective action of drugs 
that block the renin-angiotensin system [36]. Analysis in secondary 
prevention studies also suggests beneficial effects of treatment of 
hypercholesterolaemia [106] [107]. Finally studies have also confirmed that 
aspirin prevents cardiovascular events both in hypertensive [80] and diabetic 
individuals These data demonstrate that in a cohort of patients identified as 
diabetic nephropaths and therefore at high cardiovascular risk, prescription of 
therapeutic measures aimed at both delaying the rate of progression of renal 
disease and targeted at cardiovascular risk is poor. From the point of view of 
progression of renal disease, it is of particular note that a large proportion of 
the patients did not meet published blood pressure guidelines. Furthermore, 
the use of ACEi in the group of patients with sub-optimal blood pressure 
control is also low and represents a missed opportunity in terms of minimising 
risk of progression of renal disease and addressing cardiovascular risk factor
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management. It is likely that documentation in the patient records of positive 
urinalysis in only 50% of cases in part, at least, explains the low ACEi 
prescription rates in known diabetic nephropaths. It is not unexpected 
however that in those “missed” nephropaths that were identified following 
change of practice, ACEi usage was particularly poor. The significant 
omission of ACEi in the subgroup of hypertensive “missed” nephropaths 
however, further emphasises the need for a comprehensive and effective 
screening program. Having significantly improved identification of this “high 
risk” population, examination of the impact of a nurse led management 
programme on achieving accepted treatment targets formed the next step of 
this intervention.
It is acknowledged that many ‘lifestyle’ factors have a substantial impact on 
the cardiovascular risk of the population including
• Weight and Body Mass Index
• Alcohol consumption
• Smoking
• Glycaemic control
Modification of these risk factors are an essential part of the management of 
cardiovascular risk but were beyond the scope, remit and resources of these 
projects but are tackled on a routine basis by diabetic specialist nurses, in 
both primary and secondary care.
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Chapter 4:
A stepwise, nurse-led intervention algorithm: Impact over twelve months 
on Blood Pressure control and Angiotensin Converting Enzyme 
Inhibitor/Angiotensin Receptors Blocker prescription in a patient cohort 
with Diabetic Nephropathy.
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4.1 Introduction
The previous chapter has highlighted the deficiencies in care for this patient 
cohort with diabetic nephropathy and has led to the recognition that an 
assessment of the current mode of care delivery in this context is required and 
introduction of an alternative mode of care delivery should be undertaken. As 
has also been noted, the benefit and importance of blood pressure control 
and therapy with Angiotensin Converting Enzyme inhibitors (ACEi) and 
Angiotensin Receptor Blockers (AR Blockers) has been clearly demonstrated 
from evidence in the published literature. In response to this evidence, the aim 
of this chapter is to describe the introduction and outcomes of nurse led, 
algorithm driven practice which integrated primary and secondary care and 
attempted to improve blood pressure control and ACEi/AR Blockers in this 
vulnerable group of patients.
4.2 Patient Cohort
All enrolled patients attended the diabetes clinic led by a single Diabetologist 
based at a teaching hospital. A newly appointed dedicated specialist nurse 
discussed study entry with all nephropaths from consecutive patients seen in 
the diabetic clinic over an 8-month period, as reported in the previous chapter. 
All prescribed medication was recorded, and in particular, the use of ACEi, 
angiotensin II receptor blockers (ARBs) and number of antihypertensive 
medications.
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4.3 Blood Pressure Recording
An algorithm was designed to assist and standardise the identification of all 
patients with sub optimally controlled blood pressure. The nurse then ensured 
that clinic medical staff were informed of patients requiring changes in therapy 
(Figure 14). This algorithm stratified patients based on their initial blood 
pressure reading at that clinic visit. If blood pressure was above treatment 
guidelines a repeat measurement was done 30 minutes later. Based on this 
second reading those patients with blood pressure >140/80mmHg were 
targeted for intensification of their blood pressure medication. Patients with 
borderline hypertension (>135/80 mmHg but <140/80 mmHg) had a 24-hour 
blood pressure monitor fitted to identify those with blood pressure readings 
outside guidelines. The algorithm had a detailed stepwise phased introduction 
of agents to attain blood pressure control taking account of existing comorbid 
conditions.
Clinic blood pressure was measured with an automated digital blood pressure 
monitor (Omron Healthcare UK, Henfield, West Sussex, UK) after a 5-minute 
seated rest.
For patients above target (either systolic, diastolic or both), treatment changes 
were initiated, where possible, in the diabetic clinic. There were occasions 
however, when it proved difficult to initiate change in the clinic, sometimes due 
to the patient not being seen by the specialist nurse prior to their appointment 
and on other occasions by the reluctance of the medical staff to comply with 
the algorithm but choosing to rely upon their own clinical judgement instead. 
In patients where this was the case, the link between the nurse specialist and
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the Primary Care team was utilised to bring about treatment change and 
monitor progress and response to changes in therapy.
In addition to the Clinical Nurse Specialist and the Primary Care Team a 
Consultant Nephrologist was available to offer additional advice about 
treatment changes or difficult management decisions. Follow up was arranged 
with primary care and information from the follow up visits was fed-back to the 
Clinical Specialist Nurse. Once blood pressure was at target the patients were 
then seen 3 monthly by the practice nurse.
All patients with blood pressure measurement at or below target were 
allocated to routine follow up care comprising annual follow up in the diabetic 
clinic.
Although the role of both Mean Arterial Pressure (MAP) and Pulse Pressure 
(PP) remain controversial in the prediction of cardiovascular risk, it was felt 
appropriate to report the range of values in this patient cohort. Mean arterial 
pressure (MAP) was calculated using the formula MAP = [(2 x 
diastolic)+systolic] / 3. A MAP of about 60 is necessary to perfuse coronary 
arteries, brain and kidneys, with the usual range being between 70 and 110 
mmHg. The role of pulse pressure in the prediction of cardiovascular risk was 
considered as part of an analysis from data collected as part of the 
Framingham study and published in the late 1990s [108]. The authors 
concluded that in the middle-aged and elderly, cardiovascular risk increased 
with lower DBP at any level of SBP>120 mm Hg, suggesting that higher PP 
was an important component of risk. Neither SBP nor DBP was superior to PP 
in predicting CHD risk
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4.4 Results
A total of 233 patients from the original cohort of patients with diabetic 
nephropathy agreed to take part in the second phase and were recruited into 
the study with complete data available on 222 patients. The median (IQR) age 
of the patients in the study was 66(57-73) years and the gender ratio was 
153:80 (M: F). There were 203 type 2 diabetic patients and 100 of these 
patients required insulin. All patients were followed up for at least 12 months.
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4.4.1 Blood Pressure: the total population
Baseline Measurements:
Systolic and diastolic blood pressure was measured using the algorithm 
detailed in Figure 14. After every participant had been in the study for a 
minimum of twelve (12) months, measurement was made of blood pressure 
parameters, Angiotensin Converting Enzyme Inhibitor (ACEi) and Angiotensin 
Receptor Blocker use.
In the population as a whole, Median (Inter Quartile Range) systolic blood 
pressure was 145(133-160) mmHg at study start and 145(135-160) mmHg at 
study end and is illustrated in frequency charts 24a and 24b.
Median (IQR) Diastolic Blood pressure was 80(70-88) mmHg at study start 
and 76(68-84) mmHg at study end for the total group and is illustrated in 
Figures 25a and 25b.
Statistical analysis was undertaken using Wilcoxon Signed Rank Test and 
showed no statistically significant difference (p=0.836) between the two 
measurements for systolic blood pressure and p=0.056 for diastolic blood 
pressure.
Box and whisker plots (Figures 26 and 27) of systolic and diastolic blood 
pressure of the total population illustrates the distribution in the total 
population.
The median (IQR) of Pulse Pressure (PP) and Mean Arterial Pressure (MAP) 
in this cohort of patients at the start of the intervention were 100.3(93.3-110)
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mmHg and 70(55-81) mmHg respectively. At study end, MAP was 98.7(92- 
108) and Pulse Pressure was 70(58-82) mmHg. Frequency charts of Mean 
Arterial Pressure and Pulse Pressure are illustrated in Figures 28a and 28b; 
Figures 29a and 29b respectively. Box and Whisker plots (Figures 30 and 31) 
illustrate the Median (IQR) of Mean Arterial Pressure and Pulse Pressure 
respectively
Proportion of patients meeting guidelines
Analysis of the total population was undertaken to ascertain the proportion of 
patients meeting the current guidelines for Systolic Blood Pressure (equal to 
or less than 135 mmHg) and Diastolic Pressure (equal to or less than 75 
mmHg) and is illustrated in Table 8.
Table 8: Numbers of patients meeting and not meeting Systolic and 
Diastolic Targets
At diastolic target Not at diastolic target
At systolic target 39 27
Not at systolic target 43 113
In summary, 39 (17.6%) patients met both systolic and diastolic targets, 43 
(12.1%) patients had isolated systolic hypertension, whilst 113 (50.9%) 
patients met neither systolic nor diastolic targets.
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For the purposes of further analysis, patients were divided into those that met 
both targets (n=39) and those who did not meet either systolic or diastolic 
targets or both (n=183).
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Figure 24a: Frequency Chart of Systolic Blood Pressure for total
population at study start
100 190 200
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Figure 24b: Frequency Chart of Systolic Blood Pressure for total 
population at study end
100 150 200
Systolic Blood Pressure mmHg
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Figure 25a: Frequency Chart of Diastolic Blood Pressure for total
population at study start
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population at study end
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Figure 26: Systolic Blood Pressure at study start and end for the total
population
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Figure 27: Diastolic Blood Pressure at study start and end for the total
population
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Figure 28a: Frequency Chart of Mean Arterial Pressure for total
population at study start
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Figure 28b: Frequency Chart of Mean Arterial Pressure for total 
population at study end
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Figure 29a: Pulse Pressure for total population at study start
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Figure 30: Mean Arterial Pressure at study start and end for the total
population
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Figure 30: Pulse Pressure at study start and end for the total population
Pulse Pressure at study start Pulse Pressure at study end
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4.4.2 Blood Pressure: the population not at target for systolic, diastolic 
or both pressures at study start.
Systolic and Diastolic Blood Pressure
In the population not at target at study start, n=183, Median (Inter Quartile 
Range) Systolic blood pressure measurement was 150(140-167.5) mmHg; 
146.5(136-164.5) mmHg at study end and are illustrated in Figures 32a and
32b.
Median (IQR) diastolic blood pressure was 80(77-90) mm Hg at study start 
and 78(70-85) mmHg at study end and are illustrated in Figures 33a and 33b. 
Although both systolic and diastolic blood pressure fell, statistical analysis 
undertaken using Wilcoxon Signed Rank Test, showed no statistically 
significant difference (p=0.1) between the two measurements for systolic 
blood pressure but a statistically significant difference (p=0.002) for diastolic 
blood pressure between study start and end. Box and whisker plots of systolic 
and diastolic blood pressure of patients not at target at study start are 
illustrated in Figures 34 and 35 respectively.
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Figure 32a: Frequency Chart of Systolic Blood Pressure at study start:
Patients not at target at study start
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Systolic Blood Pressure mmHg
Figure 32b: Frequency Chart of Systolic Blood Pressure at study end: 
Patients not at target at study start
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Systolic Blood Pressure mmHg
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Figure 33a: Frequency Chart of Diastolic Blood Pressure at study start:
Patients not at target at study start
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Figure 33b: Frequency Chart of Diastolic Blood Pressure at study end: 
Patients not at target at study start
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Figure 34: Systolic Blood Pressure at study start and end: patients not
at target at study start
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Figure 35: Diastolic Blood Pressure at study start and end: Patients not
at target at study start
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Mean Arterial Pressure and Pulse Pressure
Mean Arterial Pressure (MAP) was 103.3(98.3-112.8) mmHg at study start 
and at study end was 100.2(93.7-108.5) mmHg and is illustrated in Figures 
36a and 36b.
Pulse Pressure (PP) was 71(57.3-85) mmHg and 70.5(58-84) mmHg at study 
start and end respectively. These data are illustrated in Figures 37a and 37b.
Again, both MAP and PP fell in this group from study start to study end 
although a statistically significance difference was detected only in MAP 
between study start and end using Wilcoxon Signed Rank Test (p=0.011) 
whilst no difference (p=0.786) could be demonstrated in Pulse Pressure. Box 
and whisker plots of MAP and PP of patients not at target at study start are 
illustrated in Figures 38 and 39 respectively
In summary, all parameters of blood pressure were decreased between study 
start and study end although only the decreases in Diastolic pressure and 
Mean Arterial Pressure reached statistical significance.
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Figure 36a: Frequency Chart of Mean Arterial Pressure at study start:
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Figure 37a: Frequency Chart of Pulse Pressure at study start: Patients
not at target at study start
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Figure 38: Mean Arterial Pressure at study start and end: Patients not at
target at study start
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Figure 39: Pulse Pressure at study start and end: Patients not at target
at study start
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4.4.3 Blood Pressure: the population at target for both systolic and
diastolic at study start.
Systolic and Diastolic Blood Pressure
In the population at target at study start, Median (Inter Quartile Range) 
systolic blood pressure was 127 (117-130) mmHg and 135(128-150) mmHg at 
study end. These data are illustrated in Figures 40a and 40b.
Median (IQR) diastolic blood pressure was 66(62-70) mm Hg at study start 
and 71(66-77) mmHg at study end and are illustrated in Figures 41a and 41b. 
Box and whisker plots of systolic and diastolic blood pressure of patients at 
target at study start are illustrated in Figures 42 and 43 respectively 
Statistical analysis was undertaken using Wilcoxon Signed Rank Test and 
showed a statistically significant increase in both systolic pressure (p<0.001) 
and diastolic pressure (p=0.002).
By study end, 23 of the 39 patients who had been at target at study start were 
outside one or both of the blood pressure targets.
Graphical representation of individual changes in both systolic and diastolic 
blood pressures (Figures 44 and 45 respectively) illustrate that of the 39 
patients at target at study start, 32 patients increased their systolic pressure. 
In addition 31 of the 39 patients had increases in diastolic pressure.
116
Mean Arterial Pressure and Pulse Pressure
The Median (IQR) of Mean Arterial Pressure (MAP) at study start was 
85.6(80.7-91.9) mmHg rising to 93.7 (85.3-101 )mmHg at study end and 
illustrated in Figures 46a and 46b respectively.
Pulse Pressure (PP) in this cohort of patients at the start and end of the 
intervention were 55 (50-65.5) mmHg and 68(56-77) mmHg respectively. 
These data are illustrated in Figures 47a and 47b respectively.
Box and whisker plots of Mean Arterial Pressure and Pulse Pressure of 
patients at target at study start and end are illustrated in Figures 42 and 43 
respectively
A statistically significant increase was detected in both Mean Arterial Pressure 
and Pulse Pressure using Wilcoxon Signed Rank Test (p<0.001).
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Figure 40a: Frequency Chart of Systolic Blood Pressure at study start:
Patients at target at study start
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Figure 40b: Frequency Chart of Systolic Blood Pressure at study end: 
Patients at target at study start
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Figure 41a: Frequency Chart of Diastolic Blood Pressure at study start:
Patients at target at study start
Diastolic Blood Pressure mmHg
Figure 41b: Frequency Chart of Diastolic Blood Pressure at study end: 
Patients at target at study start
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Figure 42: Systolic Blood Pressure at study start and end: Patients at
target at study start
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Figure 43: Diastolic Blood Pressure at study start and end: Patients at
target at study start
Diastolic Blood Pressure at study endDiastolic Blood Pressure at study start
121
Figure 44: Individual Changes in Systolic Blood Pressure from study
start to end
8 0 -
5) 4 0 -
20 -
- 2 0 -
-4 0 -
u  u  u  u  u
-»• W  CJ1 -> l (O
Case Number
122
Ch
an
ge
 
in 
Di
as
to
lic
 
Pr
es
su
re
 
(m
m
Hg
)
Figure 45: Individual Changes in Diastolic Blood Pressure from study
start to end
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Figure 46a: Frequency Chart of Mean Arterial Pressure at study start:
Patients at target at study start
2 0 -
1 8 -
^  to­
ll.
8 -
0
Figure 46b: Frequency Chart of Mean Arterial Pressure at study end: 
Patients at target at study start
6 -
2 -
0
124
Mean Arterial Pressure
Mean Arterial Pressure mmHg
Figure 47a: Frequency Chart of Pulse Pressure at study start: Patients at
target at study start
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Figure 47b: Frequency Chart of Pulse Pressure at study end: Patients at 
target at study start
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Figure 48: Mean Arterial Pressure at study start and end: Patients at
target at study start
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Figure 49: Pulse Pressure at study start and end: Patients at target at
study start
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4.4 Use of ACE inhibitors and Angiotensin Receptor Blockers
Of the total population in the study 155 (69.8%) were prescribed either an 
ACEi or Angiotensin Receptor Blocker (ARB) at the start of the study. An 
additional 18 patients of the 67 patients not receiving these medications at 
study start had been prescribed either of these medications by the end of the 
study. In addition, 2 patients were on both an ACEi and an ARB. Thus by the 
end of the study 78% of the study population were on either an ACEi or ARB. 
In the group not at blood pressure target at study start, 53 individuals were not 
prescribed either an ACEi or ARB at study start and 35 had not been 
prescribed either by study end.
Fourteen (14) patients at target for blood pressure were not prescribed either 
and ACEi or AR Blocker and as the patients had no follow up there was no 
opportunity to make changes in prescribed therapy.
Antihypertensive medication
The mean number of anti hypertensives prescribed for the whole population 
rose from a level of 1.87 at study start to 2.14 at study end and was 
statistically significant (p<0.01) and is illustrated in Figure 50.
The increase in the total group was found in the patients not at target for blood 
pressure at study start, where the mean number of anti hypertensive agents 
prescribed per patient rose from 1.86 to 2.28 (p<0.001) whilst in the group at 
target, the mean number prescribed fell from 1.95 to 1.74, although this did 
notreach statistical significance (p=0.221).
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Figure 50: Mean number of anti hypertensives at start and end of study
for those at, and not at target
2 .5 -
■  Start of study 
B  End of study
There were a total of 467 treatment interventions made during the study. Of 
these, 256 were made in the clinic at the time of patient review. A significant 
number of treatment interventions (211 out of 467) were therefore made by 
the Primary Care Team, following proactive interaction with the Clinical Nurse 
Specialist.
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4.5 Discussion
Type II diabetes is a major public health problem and with the projected 
increase in the number of patients with type II diabetes set to reach 300 
million by the year 2025, the need for strategies to slow the progression of 
diabetic nephropathy is paramount . Given this increase in patient numbers 
there is a necessity for robust management strategies to ensure that the 
progressive complications of this debilitating disease are minimised. In order 
to delay the onset and progression of diabetic nephropathy, early detection 
and effective treatment is essential. This study has utilised a nurse led 
algorithm driven approach to improve delivery of patient care. The nurse was 
specifically able to interact with and engage the Primary Care Team in the 
process of blood pressure control to ensure that patients were not missed or 
lost to follow up.
The strategies that have shown the most benefit to patients with diabetic 
nephropathy are the control of hypertension and the use of angiotensin 
blockade. In the Pima Indians, pre-diabetic blood pressure was shown to 
predict urinary albumin excretion after the onset of type II diabetes [16]. Up to 
70% of patients with type II diabetes have hypertension before the onset of 
persistent proteinuria with a correlation between the severity of hypertension 
and the subsequent development of proteinuric renal disease [16]. There is 
now clear evidence that successful treatment of hypertension in diabetic 
patients not only reduces the microvascular complications, such as 
nephropathy but also the macrovascular events frequently seen in this patient 
group [16], [36] [109]. It has also emerged that blockade of the renin
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angiotensin system has benefit over and above that of lowering blood 
pressure in diabetic patients with microalbuminuria [36], [110, 111]. More 
recently evidence suggests that Angiotensin Converting Enzyme inhibitors 
may also prevent the onset on microalbuminuria in hypertensive type II 
diabetic patients [112]. Therefore, it is imperative that we develop strategies 
that not only control hypertension to current guideline levels but that there is 
the maximal use of ACEi/ARBs to provide the best renal/cardiovascular 
protection available. In the current study we were able to demonstrate an 
increase in the number of patients achieving target blood pressure and also 
an increase in the use of ACEi/ARBs.
The use of predefined treatment guidelines or algorithms has increased over 
recent years and they are useful tools which should enhance the ability of 
clinicians to improve patient management. However unless these guidelines 
are clear and concise their publication can be potentially detrimental. The 
publication of the NICE and BHS IV guidelines on the management of 
hypertension revealed differing approaches to the same clinical problem 
leaving clinicians unclear as to the most appropriate management and the 
patient with suboptimal care.
The use of an algorithm to specify drug sequencing allows the safe stepwise 
approach to blood pressure control by utilising the synergistic mechanism of 
action of the drugs on offer, rather than the traditional management of 
maximising dosage followed by medication switches to improve blood 
pressure control. In this study, the algorithm developed relied on the timely 
initiation of angiotensin modifying drugs and then the addition of medication to 
complement both the drugs already prescribed and patient comorbidity.
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Publication of guidelines alone will not deliver an improvement in patient care 
unless they are accompanied by an implementation strategy which takes into 
account the numerous interfaces that exist in patient management which are 
potential weaknesses in ensuring success. In particular, the number of 
diabetic patients not achieving target for blood pressure or renal referral 
increased after the publication of the SIGN guidelines for diabetic nephropathy 
in 1997 [86]. The use of a nurse with a specific remit to implement the 
algorithm for control of hypertension was designed to try and tackle this issue. 
With the recent publication of the BHS IV and NICE guidelines and the 
publicity associated with the premature closure of the ASCOT trial may have 
further undermined the delivery of successful anti hypertensive treatment.
Over recent years there have been calls to improve the management of 
chronic disease. This is a consequence of the fact that chronic disease, as a 
whole, is now the leading cause of death and disability on a world-wide scale. 
World Health Organisation figures now suggest that chronic disease including 
diabetes and obesity account for 59% of the 57 million deaths annually and 
46% of the global disease burden [113]. Developing strategies to overcome 
this burden to the healthcare system needs innovation and thought to 
maximise the potential improvement for patients. There is now evidence that 
closer links between primary and secondary care improves the health care not 
only of individual patients but also for populations of patients [114, 115] [116]
. In this study we have tried to improve those links with the help of a nurse led 
care pathway that allows feedback to and from a secondary care setting into
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the patients own local health care setting. From our data 45% of the treatment 
changes were made in direct partnership with Primary Care and they were 
involved in monitoring and reporting blood pressure in all of the patients.
The British Medical Journal reported that nurse led programmes from a 
primary and secondary care setting were analysed for cost [117] [118] . The 
primary care nurse led secondary prevention of coronary heart disease was 
felt to be cost effective whereas the secondary care evaluation of nurse led 
intermediate care in the acute setting was found to be more expensive than 
standard care. Criticism can be made of the methods in the second study but 
closer inspection suggests that despite incurring higher cost initially there may 
be health benefit gained in the longer term. Our study bridges the gap 
between these 2 studies taking the best of each to deliver a service with a 
partnership between primary and secondary care.
Of some concern are those patients that were found to be at target for blood 
pressure at study entry and were then consigned to standard follow up. Blood 
Pressure in this group increased over the course of the study and this 
demonstrates it is important not to become complacent with regard to this 
group and that the current standard follow up may not be adequate. 
Treatment strategies need to be arranged to monitor these patients and the 
cost effectiveness of increased attendance at OPD balanced against the 
earlier intervention. There was no difference in number of anti hypertensive 
medications between the start and end of the study for this group, but in 
addition, this was a missed opportunity to increase ACEi/AR Blocker use.
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Clearly establishing a programme that enables patients with type II diabetes to 
be screened and treated effectively with the current level of resource will need 
more thought. Structuring such a programme will need cooperation between 
primary and secondary care to provide the best value for money and reach 
the widest possible number of patients.
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Chapter 5
Investigation of Anaemia in a selected Cohort of Patients with Type II 
Diabetes Mellitus
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5.1 Introduction
Although the prognosis for patients with diabetic nephropathy has improved 
since early reports [119] [120] , there remains an excess mortality of 70-100 
times that of an otherwise matched population [104] . Survival on dialysis 
remains poor, with up to a third of patients dying within a year of starting 
dialysis [121]. Furthermore for patients who require renal replacement 
therapy, morbidity as assessed by hospitalization is 2-3 times greater than for 
non-diabetic patients with end stage renal failure . This excess of both 
morbidity and mortality in part relates to the high incidence of cardiovascular 
disease in this patient group. The identification of mechanisms which underlie 
modifiable factors that may prevent or slow progression or improve patient 
survival in diabetic nephropathy has, therefore, become increasingly important 
and implementation of strategies which address these issues has been 
outlined in the previous chapters of this thesis.
Patients presenting with diabetic nephropathy commonly have a greater 
degree of anaemia, for the degree of renal impairment, than those presenting 
with other causes of renal failure and anaemia develops earlier than in 
patients with renal impairment from other causes [122] [123]. Recent studies 
have identified anaemia as a risk factor for the need for renal replacement 
therapy in diabetes [124] and also that a lower haemoglobin is significantly 
associated with a more rapid decline in Glomerular Filtration Rate (GFR) 
[125]. Furthermore, treating anaemia early in renal failure has been 
demonstrated to slow the rate of decline of renal function [126]. Anaemia also 
has a negative impact on patient survival and is considered to be an important 
cardiovascular risk factor associated with renal disease. A greater
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understanding of the pathogenesis of the anaemia associated with diabetes 
and nephropathy may lead to opportunities for developing interventions to 
optimise outcomes in these patients.
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5.2 Factors identified in the literature as having an impact on the 
development of anaemia in patients with Type II diabetic nephropathy
Many factors have been investigated and reported in the peer reviewed 
literature as having an impact and being responsible, to a greater or lesser 
extent, for the earlier onset of anaemia in patients with Diabetes Mellitus. 
These factors include:
1) Severe symptomatic autonomic neuropathy causing efferent sympathetic 
denervation of the kidney and loss of appropriate Epo production
2) Damage to the renal interstitium
3) Systemic inflammation
4) Inhibition of erythropoietin release.
It has also been shown that a normochromic, normocytic anaemia can occur 
before evidence of renal impairment is present. In order to clarify the 
contribution of diabetes and nephropathy to anaemia in patients with type II 
DM, this study examined the haematological and haematinic parameters of 
diabetic patients without nephropathy. A retrospective analysis was also 
carried out which investigated the longitudinal changes in haematological 
parameters of this patient group.
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5.3 Methods
Individuals were recruited from the Research Clinic of the Academic Diabetes 
Research Unit, Llandough Hospital, Cardiff, where patients are under long 
term follow up. All patients had been under follow up for a minimum of five 
years. Sixty two (62) patients gave written informed consent. All recruited 
patients had been diagnosed with Type 2 diabetes and undergo exhaustive 
yearly health checks, including formal isotope measurement of Glomerular 
Filtration Rate (GFR) and assessment of proteinuria.
Retrospective data, including Haemoglobin and GFR were collated from this 
patient group from the time of their diagnosis and referral to the diabetic clinic 
-  the retrospective samples have been labelled Study Point 1 for the purposes 
of this study.
For this study, at annual diabetic review, a blood sample was taken to 
measure serum ferritin, serum Epo levels and reticulocytes in addition to 
routine parameters including haemoglobin, haematocrit, and GFR: The 
prospective samples have been labelled as Study Point 2. As part of the 
original protocol, it had been planned that measurement of the percentage of 
hypochromic red cells would be undertaken and samples were collected and 
frozen for this purpose. During the course of the study, replacement of the 
analysers used for sample analysis within the haematology department was 
undertaken and the new analysers could not undertake measurement of 
percentage hypochromia. In addition retrospective haematological results 
were collected from the patient records for the period prior to recruitment.
140
5.4 Results
5.4.1 Demographic data
Analysis of basic demographic data of the patient group revealed a median 
patient age of 62 years with an interquartile rage of 55 to 69 years and a 
45:17 ratio of male to female patients reflecting the reported gender ratio of 
this disease.
Patients had a median (IQR) diabetes duration of 7 (5-11) years. No patients 
tested positive for neither microalbuminuria nor proteinuria at Study Point 2 or 
had done so in the past as reflected by review of medical records.
Summary data of patient characteristics is detailed in Table 9 below and 
frequency charts in Figure 51 and 52 below illustrate the patient age and 
duration of diabetes respectively.
5.4.2 Haematological Parameters at Study Point 1
Retrospective collation of data collected at diagnosis or Study Point 1, 
revealed that haemoglobin was the only haematological parameter measured 
and in Figure 53 a histogram with normal curve illustrates the frequency of 
levels found. In addition Figure 54 demonstrated levels of Glomerular 
Filtration Rate which was measured formally at that time.
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Table 9: Demographic characteristics of Patient Group (n=62)
Age (years) at Study Point 2 62(55-69)
Diagnosis (All patients) Type II Diabetes Mellitus
Gender (M: F) 45(72.5%): 17(27.5%)
Diabetes duration (years) 7(5-11)
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Figure 51: Frequency chart of Age in years of patient group at Study 
Point 2
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Figure 52: Frequency Chart of Diabetes duration of patient group at
Study Point 2.
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Figure 53: Frequency chart of Haemoglobin (g/dl) of patient group at
presentation - Study Point 1
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Figure 54: Frequency chart of Glomerular Filtration Rate (ml/min) of
patient group at presentation - Study Point 1
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5.4.3 Comparison of haemoglobin and glomerular filtration rate levels 
at Study Point 1 and Study Point 2.
Although only a small number of the patient group had anaemia as defined by 
normal values, the retrospective analysis of individual patients over time 
revealed a sustained although small decrease in haemoglobin from initial 
presentation (Figure 55) and analysis of individual changes in haemoglobin 
over time indicates that 36 of the 62 individuals (59%) had sustained a drop in 
haemoglobin (Figure 56).
Statistical analysis of this non parametric data using Wilcoxon’s Rank Signed 
test revealed a statistically significant drop (p=0.003) in haemoglobin from 
presentation to the time of study and a similar statistically significant drop in 
GFR, (Figure 57) from presentation to study (p<0.001), reflecting a reversion 
from the historically described ‘hyperfiltrative’ state to a level of ‘normal 
‘filtration which is part of the natural history of diabetes.
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Figure 55: Haemoglobin (g/dl) of patient group at presentation with
diagnosis of diabetes and at time of study
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Figure 56: Bar Chart of changes in Haemoglobin (g/dl) of individuals in 
patient group over time from presentation to time of study.
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Figure 57: Glomerular Filtration Rate (ml/min) of patient group at
presentation with diagnosis of diabetes and at time of study
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5.4.4 Haematological and Haematinic parameters at Study Point 2
Haemoglobin levels at the time of study are detailed in the frequency chart in 
Figure 58 and median (IQR) levels were 13.75 (12.5 to 15.4) g/dl. Using 
normal ranges for male (>13g/l) and female (>11.5g/l), patients were divided 
into anaemic and non-anaemic groups. At the time of investigation, eight (8) 
Male patients out of 45 were then classified as anaemic (17.8%), while 2 
female patients of 17 fell into the anaemic category (11.8%).
Median (IQR) serum erythropoietin (Epo) levels at time of study were 14(12- 
20) and are levels are illustrated in a frequency chart below (Figure 59). 
Glomerular Filtration Rate in this patient group were median (IQR) 104(89- 
120)mls per minute and are illustrated in Figure 60.
Illustration of Haematocrit, Percentage reticulocytes, Reticulocytes and 
Ferritin levels are contained in Figures 61, 62, 63 and 64 respectively 
In addition, patients were categorised into groups by haemoglobin level
Group 1: Haemoglobin lowest to 11.5g/dl: n=6
Group 2: 11.6 to 12.5g/dl: n=10
Group 3: 12.6 to 13.5 g/dl:: n=12
Group 4: 13.6 to 14.5 g/dl: n=14
Group 5: 14.6 to 15.5 g/dl: n=12
Group 6. 15.6 and higher: n=8
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Figure 58: Frequency chart of haemoglobin levels in patient group
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Figure 59: Frequency chart of erythropoietin levels in patient group
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Figure 60: Frequency chart of Glomerular Filtration Rate in total patient
group n=62
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Figure 61: Frequency chart of haematocrit in patient group
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Figure 62: Frequency chart of percentage reticulocytes in patient group
(n=62)
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Figure 63: Frequency chart of reticulocytes in patient group (n=62)
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Figure 64: Frequency chart of ferritin in patient group
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5.4.5 Relationship between measured haematological and haematinic 
parameters
Serum Epo levels (units) in relation to levels of haemoglobin (Hb) at the time 
of follow up, are illustrated in Figure 65. These data suggest an appropriate 
Epo response to the fall in Hb, as Epo levels were highest in the group with 
the lowest haemoglobin. Statistical analysis confirms a statistically significant 
difference in erythropoietin levels (p=0.016), (Kruskal Wallis) with the highest 
Epo levels in Group 1 (those with haemoglobin levels of 11.5g/dl and less) 
and the lowest Epo levels in Group 6 (those with haemoglobin levels of 
15.5g/dl and above). In addition, a significant negative correlation (Pearsons 
correlation coefficient 0.612) between Epo levels and haemoglobin was 
demonstrated (p=0.01), illustrated by the scatterplot in Figure 66.
Despite the increase in erythropoietin levels in those patients with low 
haemoglobin, there was no commensurate, normal physiological reticulocyte 
response (Pearson’s correlation coefficient=-0.134, ns). Neither absolute 
reticulocyte count (x 109/L) nor percentage reticulocyte count showed a 
statistically significant difference between the patient groups with the lowest 
Hb and those with the highest Hb (Figures 67 and 68), and there was no 
relationship between the reticulocyte count and Epo concentration (Figure 69) 
To ensure that the observed changes were not the result of iron deficiency, at 
the time of investigation, ferritin concentration (ng/ml) was determined for all 
patients (Figure 70). The results demonstrated that there was no statistically 
significant difference in the ferritin concentration between the patients with the 
lowest and highest Hb, although the patients in the lowest haemoglobin 
grouping had clinically low ferritin levels. As these patients had not mounted a
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reticulocyte response to increased erythropoietin levels it is unlikely that this 
relative iron deficiency was a contributor to the relative anaemia.
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Figure 65: Erythropoietin levels in patients divided by haemoglobin at
Study Point 2
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Figure 66: Scatterplot of haemoglobin and Erythropoietin levels in total
patient group (n=62)
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Figure 67: Reticuloctye levels in patients divided by haemoglobin at time
of study
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Figure 68: Percentage reticulocyte levels in patients divided by 
haemoglobin at time of study
2.50-
2 .0 0 -
1.50-
1.00 -
0.50-
 1 1 1 1 1----
11.6-12.5 12.6-13.5 13.6-14.5 14.6-15.5 15.6 +0-11.5
Haemoglobin (g/dl)
164
Er
yt
hr
op
oi
et
in
 
Un
its
Figure 69: Scatterplot of Erythropoietin levels and reticulocytes in total
patient group (n=62)
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Figure 70: Ferritin levels in patients divided by haemoglobin at time of
study
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5.4.6 Patient Group with decreased Glomerular Filtration Rate at time of 
study
Of the 62 patients studied, 6 patients had a glomerular filtration rate below 
normal (80 mis /minute). Analysis of this patient group revealed basic 
characteristics described below in Table 10. In summary, only one of the 
patients with a lower GFR (equal to or less than 80 mls/minute) was anaemic 
as defined by the standard criteria and that individual was a patient identified 
as potentially having an additional reason for anaemia, namely rheumatoid 
arthritis.
Table 10
GFR (mls/min) Haemoglobin (g/dl) Gender Anaemic
69 12.4 Female No
71 12.4 Female No
73 13.0 Male No
74 13.7 Male No
77 9.6 Female Yes
80 13.7 Male No
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5.5 Discussion
Anaemia is a common complication of chronic kidney disease (CKD). It is 
often more severe and occurs at an earlier stage in patients with diabetic 
nephropathy than in patients with CKD of other causes and numerous studies 
have addressed the interaction between diabetes and renal failure in its 
pathogenesis. This anaemia associated with nephropathy results from 
erythropoietin deficiency, which seems to develop in patients with type 1 
diabetes even at relatively "normal" levels of serum creatinine. Early 
erythropoietin- deficiency anaemia occurs in both Type 1 and Type 2 Diabetes 
Mellitus, although the prevalence may be higher in Type 1 Diabetes [127], 
However, numerically most patients with erythropoietin-deficiency anaemia 
have Type 2 diabetes as it is a much more common disease. There is also a 
greater prevalence in women than men but this is not related to iron stores. In 
addition, erythropoietin-deficiency anaemia is associated with the presence of 
autonomic neuropathy in patients with diabetes. In most studies to date the 
predominant risk factor for the development of anaemia in a diabetic 
population has been found to be the presence of renal disease, manifested as 
impaired renal function or albuminuria [128]
Although a small number of patients in the group were overtly anaemic, it is 
interesting to note that 60 % had an ongoing, small but significant decrease in 
haemoglobin since presentation. This may be partly accounted for by the 
effects of age, which is known to have an effect on haemoglobin levels but 
the prevalence differs markedly from that of a similarly aged Caucasian 
population of between 2 % and 6% [6]. The levels of anaemia found in this 
group of type II diabetic patients are similar to the levels described in a cohort
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of patients with Type I Diabetes Mellitus, in the recently published study by 
Thomas et al where 14% of patients were found to be anaemic [129] . It is of 
note however, that this study contained a significant cohort of patients with 
nephropathy of varying degrees, whereas the group studied within the current 
study had normal Glomerular Filtration Rates in the main and no
microalbuminuria.
This study has attempted to unravel further our understanding of the early 
onset of anaemia in diabetic patients, by separating the impact of diabetes 
mellitus from that of nephropathy. The group of patients studied have 
undergone intensive follow-up in a multi-disciplinary diabetic clinic. They, by 
self selection to attend the research clinic are a well motivated and educated 
group of patients. In contrast to studies performed in patients with
nephropathy, this study of diabetic patients without nephropathy shows a 
different picture, with the expected normal increase in Epo production in 
response to lowering levels of haemoglobin but without the expected normal 
reticulocyte response, suggesting a state of relative Epo resistance. This is 
in contrast to the anaemia associated with renal disease which is postulated 
to be a defect of “anaemia-sensing” rather than a secretory defect associated 
with autonomic neuropathy [130] Our data, demonstrating increased levels of 
Epo, suggest that diabetic patients, in the absence of renal disease, are able 
to mount an appropriate Epo response and are consistent with the 
demonstration of an appropriate response to hypoxia previously reported
[122] . One of the most potent causes of suboptimal response to Epo is
chronic inflammation and overt inflammation [128] associated with an 
increased production of cytokines such as tumour necrosis factor alpha,
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interleukin-1 and interferon gamma [131] , which might suppress erythrocyte 
stem-cell proliferation [132] . It is interesting to speculate therefore, that overt 
inflammation associated with the diabetic state may contribute to Epo 
unresponsiveness prior to the onset of nephropathy.
Although ferritin levels are not always an accurate reflection of iron status, the 
majority of ferritin levels in this patient group were within the normal range and 
no patient had evidence of overt iron depletion. This is consistent with 
previous studies which failed to demonstrate iron deficiency in a mixed cohort 
of Type 1 and 2 diabetics [133]. These studies demonstrated elevated iron 
indices to be more common in patients with diabetes and suggested that 
excess iron may have a role in the development of diabetes.
Recent studies have highlighted an association between anaemia, the 
development and progression of diabetic nephropathy. There is also a high 
cardiovascular risk in patients with diabetic nephropathy and a clear 
association between anaemia and abnormal cardiac function. That 
development of anaemia in diabetes may pre-date any abnormality in renal 
function is therefore an important observation. Furthermore, understanding of 
the mechanism by which this occurs may provide the opportunity to develop 
therapeutic options which may, therefore, improve patient outcomes.
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Chapter 6
The future: Managing the progression of renal disease at the interface 
between Primary and Secondary Care
171
6.1 Introduction
The increasing impact of diabetes on the prevalence of chronic kidney 
disease has been highlighted in the previous chapters of this thesis. The focus 
of the work described the development and results of strategies for screening 
and identifying the ‘at risk’ diabetic population in terms of renal disease and 
the associated cardiovascular risk factors, accurately and efficiently. In 
addition, data relating to the management of a group ‘at risk’ for the 
development of chronic kidney and cardiovascular disease at the interface 
between primary and secondary care has been reported. Outwith the 
‘success’ and associated resource implications the striking finding that yearly 
follow-up of those at target for blood pressure control and prescription of ACEi 
and/or Angiotensin Receptor Blockers was inadequate, serves to emphasis 
the size of the problem. Studies have shown that the impact of renal disease 
can be mitigated and that early detection, timely and appropriate referral is 
paramount, especially as a large proportion (between 30 and 50% ) of 
patients with CKD die from cardiovascular disease rather than progressing to 
end stage renal failure [134] [135] .
Although it is outwith the scope of this thesis to consider the impact on 
individual of late referral to nephrology, it can be summarised by the impact on 
mortality of late and early referral reported by Winkelmayer et al and 
illustrated in Figure 71 [136] and by the length of time, up to three years, it 
takes for referral to a nephrologists to have an impact on levels of creatinine
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World wide there is a large cohort of patients either at high risk of developing 
renal failure because of co-existing disease like diabetes or already with a 
degree of renal impairment, all of whom require ongoing, complex care in a 
multi-agency setting to ensure that evidence based practice is implemented 
and the best patient outcomes are achieved.
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Figure 71: Referral patterns and patient mortality
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Kaplan Meier plot of actuarial survival by timing of referral in 
propensity score matched population (n-2078)
Winkelmayer WC, Owen WF, Levin R, Avorn J. A Propensity Analysis of Late Versus Early Nephrologist 
Referral and Mortality on Dialysis Journal of the American Society of Nephrology. 2003;14:486-92.
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The previous chapters of this thesis have highlighted the potential 
improvement in screening and detection of diabetic nephropathy within one 
selected patient cohort of 200 patients. In addition, management of the blood 
pressure of those patients outside nationally agreed targets by a dedicated 
nurse specialist have shown a degree of success but the cost and resource 
implications are considerable. Outside the research framework, it is not 
practicable to undertake this type of initiative. It is not feasible nor desirable to 
run any service if it is dependent upon one individual and the cost of 
employing a nurse specialist, even if such individuals were available, for each 
200 patients at risk of developing diabetic nephropathy would be prohibitive to 
the National Health Service. In addition, there are large cohorts of patients 
with diabetes who are managed exclusively in Primary Care and would 
therefore not be available to Secondary Care for screening.
In terms of NHS resources, diabetes is just one component of a large number 
of patients at risk of or in the early stages of developing renal failure from 
other causes. The need to reform the service to undertake the primary, 
secondary and tertiary prevention of renal disease is essential.
Currently the proportion of NHS income spent on renal replacement therapy, 
in comparison to the general nephrology budget can best be described as an 
inverted triangle, with the broad base representing the spending on dialysis 
and transplantation (Figure 72).
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In an attempt to standardise patient identification, stages of chronic kidney 
disease have been defined by the NKF-K/DOQI guidelines and are detailed in 
Table 11 below. In addition to levels of Glomerular Filtration Rate, stages 
must have an anatomical component - i.e. evidence of kidney disease and 
must also have a temporal component -  i.e. have been present for at least 3 
months.
These stages have been used as a basis for formulating strategies for referral 
and management across primary and secondary care, to deal with the large 
numbers of affected individuals.
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Table 11: Definition and stages of Chronic Kidney Disease according to 
NKF-K/DOQI guidelines
Stage Description GFR (m l/m in/l.ram2)
At increased risk e.g. 
known diabetes or 
hypertension
£ 60 (with CKD risk 
factors)
1 Kidney damage with 
normal or increased 
GFR
£90
2 Kidney damage with 
mildly decreased GFR
60-89
3 Moderately decreased 
GFR
30-59
4 Severely decreased 
GFR
15-29
5 Kidney failure <15 or dialysis
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6.2 What is the problem?
The size and scale of this problem of diagnosis and management of CKD, of 
which those with diabetic nephropathy comprise one of the high risk groups, is 
a challenge for many parts of the National Health Service especially as it 
comprises around 20% of the prevalent patient numbers new to renal 
replacement therapy [137],
As reported by Amhad et al in 2006, service planning for the care of patients 
with CKD is difficult, as there are no data available on patients approaching 
renal failure and there is no information on the facilities available to look after 
this patient group [138]. The authors contrast the paucity of information 
available for the pre RRT phase with the wealth of data available on the 
patient status and facility characteristics of those on RRT, where the 
infrastructure for collection, collation and distribution of data has been 
centrally funded. The authors then reported data from seventy (70) units in the 
United Kingdom in which they attempted to quantify the number of patients 
attending nephrology services. The data from twenty five units showed that 
the median (IQR) ratio of prevalent CKD patients to prevalent renal 
replacement therapy patients was 3.7(2.7-5.7) and the median (IQR) ratio of 
CKD Stage 4 and 5 patients /prevalent RRT patients was 0.6(0.4-1.1). The 
authors estimate, therefore, that UK wide there are around 140,000 CKD 
patients under the care of nephrologists with 23,000 of those at stage 4 or 5.
179
6.3 Impact of geography: Data from Wales
Estimates of patient numbers in Wales from the National Standards 
Framework for Renal Disease for Wales [139] are detailed below in Table 12 
and identify a total CKD population of around 400,000. It should, however, be 
remembered that of the 150,000 patients at Stage 3, only <1.5% will progress 
to end stage renal disease.
Table 12
Stage Percentage Number
Stage 1 4% 120,000
Stage 2 4% 120,000
Stage 3 5% 150,000
Stage 4 0.2% 4000
Stage 5 0.08% 2400
Some insight on the proportion of patients with CKD under the care of the 
nephrologists, in comparison with those being looked after by others (Primary 
Care and other medical specialities) was gained from a retrospective study by 
the author comparing two hospitals of similar size and catchment area, both in 
the same region and with similar socio-economic background. One of the two 
hospitals has a renal outreach clinic and a ward consultation service. Audit of 
two separate weeks identified approx 500 individual patients with serum 
creatinine greater than 150pmol/l, which were the current referral guidelines 
and although not providing an accurate reflection of renal status was the only
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way to identify patients, given the limited information recorded by 
biochemistry. An algorithm detailing the differences in patient referral to 
nephrology between the hospital with a renal presence, in comparison with 
the hospital without, is shown in Figure 73 below. As can be seen from the 
percentages in the algorithm, of the 355 living patients, 55% from the centre 
with nephrology input were not known to nephrology whilst 93% of the 
patients from the centre without nephrology input were unknown to the 
nephrology service. Of the 195 patients not known to nephrology, it appears 
appropriate that a number of these patients were not known to nephrology, as 
further biochemistry results reveal a return to normal levels indicating an acute 
episode of renal failure. Of more concern, was the group of 106 patients who 
were not known to nephrology but who either had no follow up result (n=45) or 
had a follow up result that showed worsening renal function (n=61). This 
indicates that in this small sample, there were 160 patients under nephrology 
follow up but in addition there were 92 patients who were not under follow-up 
by the nephrology service but probably should have been.
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Figure 73: Algorithm of referral/non referral of patients with elevated 
plasma creatinine
Living 71% - 83% Dead 29%-17%
Under follow up 45% - 7%
No follow up renal function 
18% - 17%
Renal function improved 
69% - 54%
Not known to nephrology 55% - 93%
Renal function deteriorated 
13% - 28% 
(12-49)
All patients with Serum Creatinine >150pmol/l 
identified retrospectively from Biochemistry 
database
Hospital with renal input 
Hospital without renal input
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Geography and access to specialist services impacts not only upon issues 
surrounding referral to nephrology, but also upon the take-on rate for dialysis 
of patients living at some distance from renal centres. These issues are 
illustrated pictorially in Figure 74, taken from a study from White et al [140] . 
This paper highlighted that the prevalence of haemodialysis (HD) fell 
significantly with increasing travel time from unit and that this was not 
influenced by deprivation indices. Prior to the opening of a new HD unit in 
Aberystwyth, prevalence in the surrounding area was significantly lower than 
for Wales as whole but within 2 years, prevalence had risen to approximate 
national levels. In Haverfordwest, an area more than a 30 min drive from any 
current facility, prevalence is consistently and significantly lower than for 
Wales as a whole and has not shown the growth seen elsewhere in the 
country.
Data from Canada, Figure 75 [141], has previously demonstrated, in addition 
to a lower take-on rate, distance from nephrology services impacts upon the 
mortality and morbidity of patients with renal disease .
The geography of Wales means that particular solutions need to be thought 
out for a number of patients living in Wales, to compensate for the difficulties 
inherent in the geography of the area.
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Figure 74: Drivetimes for centres serving Wales
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Figure 75: Proximity to nephrologists: levels of mortality and infection.
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6.4 Solutions and Responses to Problems
6.4.1 National Service Framework for Renal Disease in Wales
The National Service Framework for Renal Disease in Wales [139] 
commissioned in 2004 and published in March 2007 comprises the following 
modules
Module 1: Care for Children and Young People
Module 2: Prevention of Chronic Kidney Disease and Management of
Acute Renal Failure
Module 3: Effective Delivery of Dialysis
Module 4: Organ Donation and Transplantation
Module 5: Alternative Models of Care.
Module 2, the Prevention of Chronic Kidney Disease and Management of 
Acute Renal Failure is directly relevant to the work undertaken as part of this 
thesis and highlights the care of patients being cared for at the interface 
between Primary and Secondary care. Following the publication of a detailed 
‘Standards’ document two main outcome measures for Module 2 scheduled 
for complete implementation Wales-wide by 2008 were highlighted:
• The quality of monitoring patients at risk will have been improved by 
implementing an agreed common method for measuring renal 
impairment, i.e. eGFR.
Glomerular Filtration Rate (GFR) is the most commonly used measure of 
kidney function. The gold standard for GFR measurement uses compounds
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which are injected into the blood stream and are filtered in an unaltered state 
by the kidney. Traditionally compounds that can be used include those such 
as Inulin, the excretion of which can be measured by timed samples of blood 
and urine from which the excretion of Inulin can be measured. Other 
substances which may be used include Chromium labelled EDTA and radio 
contrast e.g. lohexol. All these methods are labour intensive, expensive and 
have considerable resource implications in terms of staff time, finance and 
patient availability. This makes these methods unsuitable for use as a 
screening tool in a large ‘at risk’ population. An alternative method is to collect 
timed urine collections, normally over a twenty four hour period. This method 
is time consuming and is open to much interference as the accuracy of the 
totality of the collection is difficult to ascertain. GFR declines naturally with age 
and after 30 years GFR may decline by between 4 to 10 millilitres per minute 
per decade.
Because of the difficulties, costs and logistical difficulties of obtaining GFR 
measurement, the standard method for many years has been serum 
creatinine. This measurement is simple and easy to do as well as being a 
cheap test to undertake. Among the negatives are the fact that serum 
creatinine is a static measurement of a dynamic process; that although 
creatinine rises with a falling GFR, the relationship is not linear; serum 
creatinine can remain in the normal range until the GFR reaches 50%; non 
renal elimination is increased in CKD; may be influenced by diet; is affected 
by muscle mass (in particular this may have an effect in relation to age, 
gender and race); can be influenced by certain drugs e.g. trimethoprim.
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Most experts in the field agree that the simplified and agreed standard MDRD 
equation which requires plasma creatinine, age, gender, race is the most 
accurate and simple measure of renal function in an ‘at risk’ population. This 
has been accepted as the validated method which has been used in the UK. 
There are alternatives methods, but all have limitations including MDRD 
equation. The MDRD equation has limitations which include 1) that there is 
the potential for interference from bilirubin, ketones and protein levels 2) that 
there is a limitation to its use in the healthy population who have greater 
muscle mass and better diet; and 3) it is of limited value in the acutely ill as 
this condition is rarely a ‘steady state’ and immobilisation, malnutrition and 
catabolic illness may all alter creatinine production. Although there are 
limitations associated with the use of the MDRD equation, its use is an 
improvement on the use of serum creatinine alone. The relationship between 
serum creatinine and eGFR result in the previously audited patient group 
described above is illustrated in Figure 76 below and highlights the differing 
eGFR results obtained from similar serum creatinine results.
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6.4.2 Introduction of Quality Outcomes Framework (QOF)
Renal disease has been introduced as a domain in the Quality Outcomes 
Framework for the first time in 2006 in Wales. The framework has four 
outcome measurements detailed below
CKD 1- generation of a register of patients with Stage 3, 4 or 5 Chronic 
Kidney Disease based on eGFR. (6 points awarded)
CKD 2 -  % of patients with record of blood pressure recorded in the last 15 
months (6 points awarded)
CKD 3 - % of patients with blood pressure below 140/85mmHg recorded in 
the last 15 months (11 points awarded)
CKD 4 - % on CKD Register prescribed an Angiotensin Converting Enzyme 
Inhibitor or Angiotensin Receptor Blocker (unless contraindicated) (4 
points awarded)
Anecdotally, Primary Care practitioners have indicated that the majority of the 
information required to gain 26 out of the 27 available points from the renal 
outcome measures were already collected as part of other chronic disease 
registers, in particular cardiovascular, diabetes, hypertension or stroke.
The key change for the NHS was the fact that the collection of these data 
highlighted the number of patients in Wales with Stages 3-5 CKD.
Having collected and collated renal outcome data on their patients, primary 
care practitioners have received extensive guidance on appropriate referral of 
patients for nephrology opinion from many sources including advice from the 
Royal College of General Practitioners [142],
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6.4.3 Impact of eGFR and Renal QOF Introduction
The introduction of the eGFR and the renal Quality Outcomes Framework in 
Wales has had an impact both on nephrology referral and pathology requests. 
The scheme has been piloted and reported in the Gwent area. The number of 
new patient referrals to Gwent has almost doubled since the introduction of 
the eGFR and renal QOF outcomes and is detailed in Figure 76 below. These 
data replicate data published recently by Richards et al [143] reporting the 
impact of the introduction of eGFR and a Disease Management Programme 
(DMP) in the West Lincolnshire Primary Care Trust where monthly referral 
numbers increased by 2.7 times the previous monthly average but then fell by 
42% following introduction of the referral assessment service as part of the 
DMP in October 2005.
The impact of this number of referrals on the capacity of secondary care 
nephrology services in Wales, in the long term is not sustainable. However it 
should be noted that in the study by Richards et al after approximately six 
months, the authors identified that ‘steady state’ had been achieved, with an 
average of 5 new Stage 4 and 5 patients being identified, which was within 
the capacity of the local services. Unfortunately, the decrease in referrals has 
not been replicated in Wales where numbers continue to grow and are now 
running between 80 and 90 per month.
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The impact of the introduction of eGFR reporting on the pathology services is 
detailed below in Figure 77. Monthly levels of Urea and Electrolyte requests 
sent to Pathology rose from around 28,000 per month to 34,000 per month 
sixteen (16) months later. It should be noted that the increase in uptake was 
not really apparent until April 2007 although eGFR and the QOF had been in 
place since April 2006. This could be accounted for by the fact that despite the 
outcome measure for undertaking eGFR being required in April 2006, 
payments were not made available until April 2007.
It is clear that the identification of renal disease impacts not only upon 
nephrology services but also upon those services providing pathology 
support.
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6.4.4 Impact on Quality and Outcomes of Referrals
Since the completion of the work associated with this thesis, an audit of the 
quality and outcomes of this increase in referrals has been carried out. This 
audit would determine if each referral had sufficient information to allow 
nephrologists to decide
a) Whether the referral was appropriate -  did this patient need to see a 
nephrologist or would referral to another medical speciality have been 
more appropriate?
b) Whether the information provided was sufficient -  with particular 
emphasis on if renal function was abnormal what was the historical 
context of this abnormal finding and whether the information given 
enabled appropriate prioritisation of the referral in relation to others?
The audit was extended to look at the outcome of the first outpatient 
appointment to see whether each referral could have been dealt with 
differently.
Audit Results
Of the new referrals, seventy six percent (76%) came from Primary Care, with 
twenty four percent (24%) from Secondary Care and are illustrated in Figure 
78 below.
Of these referrals, analysis was then undertaken of the appropriateness and 
quality of the referrals to understand whether the guidelines provided sufficient 
information to enable non-nephrologists to refer appropriately (Figure 79). 
Fifty seven percent of the patient referrals were given outpatient
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appointments, 13% of the referrals were inappropriate and 30% had 
inadequate information to enable a decision to be made. In addition, analysis 
was then undertaken of the outcome of the first outpatient referral to assess 
whether these referrals had been appropriate (Figure 80). Of the patients 
given outpatient appointments, 71% had at least one follow up appointment, 
19% were discharged from follow-up after one appointment, 9% did not attend 
for appointment and 1% were referred to the renal replacement therapy 
service.
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6.4.5 Care Pathway Development
•  A care pathway will be developed for the care of people at risk of renal 
disease and how the progression of the disease will be delayed 
through proactive management.
The work highlighted in this thesis, recognises that it is not possible for 
Nephrology services to do everything required to screen and manage care of 
patients with renal disease. It also recognises that the partnership of primary 
and secondary care and that the management of that interface is the key to 
success. In combination with the work of the NSF the emphasis is focused on 
a more structured referral pathway based on Renal Association and Royal 
College of General Practitioner guidelines [142], The development and 
introduction of a care pathway in Wales has needed the cooperation and 
involvement of Local Health Boards, Local Medical Committees and support 
from the Welsh Assembly Government. The challenge of managing the 
increase in patient numbers within limited resources and ensuring appropriate 
timely referrals is essential.
The first objective in Wales is to run a pilot of a care pathway in Gwent and 
following a period of assessment and redesign, as necessary to extend the 
pathway to the rest of Wales. The pathway is designed to manage patient 
entry and exit from Nephrology services. The care pathway will utilise the Map 
of Medicine, Nephrology Pathway on http://www.mapofmedicine.com/ 
to create a shift to:
-  Better use of local resources
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-  Increase collaboration among GPs and secondary care to 
improve patient care
-  Mobilise the local health organisation and align it with the new 
pathways.
The Map of Medicine is accessible to all Health Care Professionals and 
consists of flow charts with information ‘i’ boxes to help in the decision making 
process. The information in the ‘i’ boxes can be updated on a regular basis as 
the evidence base changes. It should be noted that this development is 
dependent upon the skills and interests of individuals in using Information 
technology to support their practice. In common with other IT initiatives, care 
will have to be take to ensure that all members of the multi-disciplinary team 
have appropriate skills and have access to appropriate equipment during their 
working day. If this is not so, then the use of these tools may be restricted. An 
essential addition to the pathway is the incorporation of a referral proforma 
(Figure 81), acceptance of which was key to the successful implementation of 
the pathway.
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Figure 81: Referral Proforma
Chronic kidney disease Referral Proforma -  Gwent Health Community
Patient details
Name
Address
dob 
NHS number
GP Details
Name
Address or practice stamp
Hospital number
Postcode
M /F
Home tel no 
Mobile tel no 
Ethnic origin
Fax number 
Date of referral
History and examination:
• General medical history
• Medication including 
recent changes
• Examination (especially 
BP. oedema)
Previous results:
Ail previous serial eGFR 
(creatinine) results with dates
Current results:
Urine dipstick results for blood and protein 
urine PCR (if indicated)
Blood count
Results of renal USS if available 
(although this should not 
necessarily delay referral)
eGFR
serum creatinine 
urea
potassium
albumin
calcium
phosphate
cholesterol
PTH (if indicated)
Please send/fax to: Nephrology Unit Royal Gwent Hospital, Newport on 
01633-234798
To discuss patient's condition, please telephone: 02920 748467
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6.5 Models of Care and Workforce Issues
The importance of collaboration between Primary and Secondary Care has 
been emphasised in chronic disease conditions other than CKD in particular 
the use of ‘stepped care’ models [144] [145]. In these models, hospital 
consultant staff work closely with GPs and may undertake clinics in Primary 
Care. Patient care is organised in four levels ranging from care delivered 
entirely in Primary Care to that delivered entirely in Secondary Care. Within 
the stepped care model, GPs are responsible for the initial diagnosis and 
initiation of treatment, with nurses playing a prominent role in following up and 
managing patient progress. Specialist care is provided as necessary with the 
most complex cases being taken over entirely by Secondary Care.
The role of Information Technology has been highlighted as an essential 
component of chronic disease management at the interface between Primary 
and Secondary Care [146] . Klebe and his colleagues highlight the input of the 
Department of Health in producing an information strategy for renal services 
which recommends that electronic care plans should be developed which can 
be shared across the care interface. The strategy includes the integration of 
clinical records and a facility for calculating GFR and utilising existing patient 
data to identify patients with CKD. In addition, the authors are currently setting 
up a clinical decision making support system for nephrology.
Patient self management is considered to be an essential component of a 
successful chronic disease management programme. Information technology 
has been used to set up Renal Patient View https://www.renalpatientview.org/ 
which enables computer literate individuals to view and share their own 
results and information. This information will enhance the experience of a
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group of patients with CKD and empower them with information to help them 
manage their own treatment provided that sufficient safeguards on data 
protection and confidentiality can be guaranteed.
6.6 Implementation
The focus of much of the implementation and operationalisation of the care of 
patients at ‘high risk’ of developing renal failure has been around the 
education and development of the knowledge base of the medical staff, both 
in Primary and Secondary Care.
However, evidence from Primary Care itself suggests that responsibility for 
much of this work will ultimately be the responsibility of the nursing staff. Work 
from Brighton and Hove Primary Care Trust
http://www.brightonandhovepct.nhs.uk/healthprofessionals/generalpractice/qualitvindi 
cators/documents/NURSEROLEinGMSQQF200607update.doc has highlighted that 
at least two of the QOF renal targets and outcomes are measured and 
operationalised by members of the Primary Care nursing team. The role, 
education and training of nurses involved in the care of this patient group will 
be paramount.
A combination of the adoption of the care pathway and the work done in this 
thesis encompasses both nurse led management and nurse led referral of 
patients and is generalisable to all geographical areas of Wales.
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6.6.1 Secondary Care
The entire focus of care within Nephrology in Secondary Care is around 
preparation for dialysis including patient education and renal replacement 
therapy and its management. In undergraduate nurse training, input on renal 
issues remains focused on renal failure issues in particular and although the 
focus is changing onto chronic disease management, it is still around the 
management of those with the disease rather than focusing on preventing or 
slowing disease development.
All follow- up care of the numerically large group of patients who would benefit 
from preventive care is focused around medical follow up in secondary care 
with very little nursing input. It is possible that lessons could be learned from 
the development of the anaemia coordinator role within secondary care, as 
the similarities in the role requirement are evident - The patient group is large; 
the evidence base is good; patients require regular and ongoing monitoring 
and changes in therapy, the interface between primary and secondary care is 
crucial to success.
The role of the Consultant Nurse has two key components which would make 
the development of this role, in preventative disease management, ideal. Part 
of the role of the Consultant Nurse is the remit to incorporate research into 
patient care. Having research skills would enable the evidence base on 
preventing disease to be kept up to date on an ongoing basis. This is a very 
important but often overlooked essential of having a viable, long term tool for 
disease management.
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The second component is the management of nurse-led clinics. Large 
numbers of patients could be managed in the early stages of CKD by nurses 
in Primary and Secondary Care. As has been shown in Chapter 4, the input of 
a nurse specialist in conjunction with expert advice from consultant 
nephrology staff, as required, had an impact on alterations made to patient 
therapy at the Primary and Secondary Care interface, However, there is 
neither funding nor manpower available to make this a viable option for the 
future. It is possible that a Consultant Nurse could have an impact on large 
numbers of patients if the remit included the preparation, coordinating and 
updating of education, training and competency materials for use in Primary 
Care. This would enable patients to be dealt with appropriately in Primary 
Care and those who require specialist input to receive increasing input from 
Secondary Care as required.
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6.6.2 Primary Care
The pressure on nurses in Primary Care to become involved in and take 
responsibility for the care of particular patient groups is heavy and it is 
important that the profile of renal disease is as high as other chronic disease 
states. It is incumbent on people who are promoting renal disease 
management to ensure that they engage with those individuals and ensure 
that the support they receive meets the professional development needs of 
the staff as well as the needs of the patient group. The education of Primary 
Care Professionals in evidence-based, appropriate and timely referral to 
Nephrology services will be an ongoing process which will require frequent 
and timely updating, as the evidence base changes and remains dependent, 
to a large extent, on the good will and enthusiasm of motivated individuals, 
rather than being part of permanently funded infrastructure support.
Anecdotal reporting from nurses working in Primary Care who attended 
education sessions run by the multi-disciplinary renal team highlighted the 
paucity of available information on the practicalities of screening patients. 
Whilst welcoming the pathophysiological knowledge and presentation of the 
evidence relating to blood pressure control, inclusion of training and 
information materials with basic information, for example for microalbuminuria 
screening -  methods, appropriate equipment and timing of samples was felt to 
be one of the aspects which could be developed.
The issue of lack of training for Primary Care nurses is highlighted in a report 
from December 2007 published online at Health Care Republic. 
http://www.healthcarerepublic.com which stated that one in six nurses 
involved with QOF work had been asked to carry out tasks they felt were
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beyond their competence. In addition, 30 per cent have been asked to carry 
out QOF-related work for which they had no formal training. A significant 
minority —  10 per cent —  of nurses employed in practices said they would 
carry out QOF work allocated by their employer even if they had not been 
properly trained. The issue of adequate training, competence and supervision 
must be tackled to ensure long term success of any initiative.
Much education and training work is being undertaken by individuals in 
isolation and it would be useful to consider the model of ‘Do Once and Share’ 
highlighted by Klebe et al [146] where new Information Technology knowledge 
is shared across specialities nationally, thereby saving time and reducing 
duplication.
Nationally accredited education, training and competency packages based on 
work could be put into place to support nursing staff in both Primary and 
Secondary Care. This would have the best chance of success if it was 
facilitated by the involvement of national organisations involving Practice 
Nurse organisations and the Royal College of Nursing.
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6.7 Conclusion
Increasing numbers of patients are living with chronic disease within a health 
care system that is set up, in the main, to cope with acute illness. Although it 
is clear that redesign of the service is necessary, as so often, the issue of use 
of funding lies at the heart of much of the discussion. Preventative medicine 
and the distribution of finite resources remains the most difficult question 
facing both clinicians and politicians. The philosopher, Isaac Singer Berlin, 
illustrated the predicament that preventative health care faces, by constructing 
the analogy of a bystander on a river bank watching increasing numbers of 
drowning men floating down the river. Having saved a few by heroic effort, the 
bystander is faced with a dilemma -  should he continue to try in vain to 
continue rescuing the drowning or should he abandon those already in the 
water and run upstream to try and stop people falling or being pushed into the 
water?
It is simple, in the abstract, to set out long term goals for the prevention of 
disease but it remains much more problematic to divert funding into 
prevention if this has an impact on the care given to individuals already 
suffering from disease. Policy making tends to focus on the current situation 
rather than potential situations in the future and the spectre of newspaper 
headlines highlighting particular individuals who are either having no 
treatment or poor quality treatment for established disease can make it difficult 
for the longer term goals focusing on prevention and the slowing of 
progression of renal disease, to gain support.
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Rigorous appraisal and re-evaluation of the use of current funding as well as 
injections of new funding are essential to redesign services for the future ih 
primary, secondary and tertiary care.
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